Tables | Volume 33 | HIV Surveillance | Reports | Resource Library | HIV/AIDS

Table 1a. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	31,332	—	30,461	—	29,730	—	28,948	—	24,269	—
Female	7,512	—	7,300	—	7,084	—	6,917	—	5,439	—
Transgender woman/girl^b	675	—	612	—	627	—	652	—	638	—
Transgender man/boy^b	22	—	33	—	48	—	45	—	40	—
Additional gender identity^c	11	—	15	—	15	—	23	—	17	—
Age at diagnosis (yr)
<13	130	0.2	105	0.2	87	0.2	57	0.1	57	0.1
13–14	26	0.3	25	0.3	20	0.2	21	0.3	12	0.1
15–19	1,715	8.1	1,786	8.5	1,719	8.2	1,648	7.8	1,248	6.0
20–24	6,915	30.9	6,466	29.3	6,109	28.0	5,969	27.6	4,822	22.3
25–29	7,947	34.6	7,723	33.1	7,711	32.7	7,402	31.4	6,061	26.1
30–34	5,641	25.8	5,672	25.8	5,673	25.6	5,673	25.3	5,197	22.8
35–39	4,210	20.3	4,260	20.1	4,209	19.5	4,140	19.0	3,409	15.6
40–44	3,245	16.5	2,980	15.2	2,971	15.1	2,974	14.9	2,515	12.4
45–49	3,046	14.6	2,930	14.0	2,780	13.4	2,575	12.6	2,072	10.4
50–54	2,856	13.1	2,637	12.4	2,455	11.8	2,312	11.3	1,857	9.1
55–59	1,882	8.6	1,872	8.5	1,843	8.4	1,832	8.4	1,575	7.3
60–64	1,080	5.6	1,083	5.4	1,046	5.2	1,107	5.4	885	4.3
≥65	859	1.7	882	1.7	881	1.7	875	1.6	693	1.2
Race/ethnicity
American Indian/Alaska Native	216	9.1	200	8.3	173	7.2	205	8.5	201	8.3
Asian	931	5.2	930	5.1	868	4.6	739	3.9	637	3.3
Black/African American	16,799	41.7	16,279	40.1	15,786	38.6	15,503	37.6	12,856	31.0
Hispanic/Latino^d	10,101	17.6	9,941	17.0	9,956	16.7	9,896	16.4	8,008	13.1
Native Hawaiian/other Pacific Islander	38	6.7	51	8.8	61	10.3	66	10.9	66	10.8
White	9,885	5.0	9,643	4.9	9,448	4.8	9,070	4.6	7,843	4.0
Multiracial	1,582	23.2	1,377	19.7	1,212	16.9	1,106	15.0	792	10.5
Transmission category^e
Male sex at birth (≥13 yrs at diagnosis)^f
Male-to-male sexual contact	25,948	—	25,346	—	24,545	—	23,975	—	20,572	—
Injection drug use	1,189	—	1,292	—	1,407	—	1,381	—	1,178	—
Male-to-male sexual contact and injection drug use	1,539	—	1,470	—	1,465	—	1,524	—	1,105	—
Heterosexual contact^g	3,251	—	2,902	—	2,877	—	2,669	—	2,012	—
Perinatal^h	10	—	14	—	16	—	20	—	9	—
Otherⁱ	15	—	17	—	21	—	19	—	20	—
Subtotal	31,952	24.2	31,041	23.3	30,331	22.6	29,589	21.9	24,897	18.3
Female sex at birth (≥13 yrs at diagnosis)^f
Injection drug use	1,034	—	1,086	—	1,105	—	1,154	—	855	—
Heterosexual contact^g	6,380	—	6,131	—	5,928	—	5,730	—	4,536	—
Perinatal^h	48	—	51	—	46	—	47	—	51	—
Otherⁱ	8	—	7	—	7	—	7	—	7	—
Subtotal	7,470	5.4	7,275	5.2	7,086	5.1	6,939	4.9	5,449	3.8
Child (<13 yrs at diagnosis)
Perinatal	107	—	88	—	68	—	46	—	44	—
Otherⁱ	23	—	17	—	19	—	11	—	13	—
Subtotal	130	0.2	105	0.2	87	0.2	57	0.1	57	0.1
Region of residence^j
Northeast	6,211	11.1	5,987	10.7	5,565	9.9	5,312	9.5	4,271	7.6
Midwest	5,172	7.6	5,115	7.5	4,940	7.2	4,748	6.9	4,127	6.0
South	20,274	16.6	19,725	16.0	19,412	15.6	19,181	15.3	15,689	12.4
West	7,895	10.3	7,594	9.8	7,587	9.7	7,344	9.4	6,316	8.0
Total	39,552	12.2	38,421	11.8	37,504	11.5	36,585	11.1	30,403	9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fData include transgender and additional gender identity persons.
^gSexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
ⁱOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^jData are based on residence at time of diagnosis of HIV infection.

Table 1b. Diagnoses of HIV infection, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	31,774	—	30,825	—	30,098	—	29,277	—	24,515	—
Female	7,617	—	7,394	—	7,164	—	6,998	—	5,480	—
Transgender woman/girl^b	678	—	614	—	629	—	654	—	640	—
Transgender man/boy^b	22	—	33	—	49	—	45	—	40	—
Additional gender identity^c	11	—	15	—	15	—	23	—	17	—
Age at diagnosis (yr)
<13	130	0.2	105	0.2	87	0.2	57	0.1	57	0.1
13–14	26	0.3	25	0.3	20	0.2	21	0.2	12	0.1
15–19	1,725	8.1	1,798	8.4	1,736	8.1	1,654	7.8	1,256	5.9
20–24	6,988	30.9	6,532	29.3	6,171	28.0	6,026	27.5	4,867	22.3
25–29	8,018	34.6	7,786	33.0	7,788	32.7	7,461	31.4	6,103	26.0
30–34	5,706	25.9	5,734	25.9	5,731	25.7	5,730	25.3	5,233	22.7
35–39	4,280	20.4	4,312	20.1	4,243	19.5	4,179	19.0	3,445	15.6
40–44	3,302	16.6	3,015	15.2	3,012	15.1	3,013	15.0	2,540	12.4
45–49	3,105	14.7	2,971	14.1	2,824	13.5	2,612	12.7	2,094	10.4
50–54	2,901	13.2	2,687	12.5	2,504	11.9	2,342	11.3	1,883	9.1
55–59	1,930	8.7	1,907	8.6	1,871	8.4	1,869	8.5	1,599	7.3
60–64	1,107	5.6	1,106	5.5	1,066	5.2	1,131	5.4	901	4.3
≥65	884	1.8	903	1.8	902	1.7	902	1.6	702	1.2
Race/ethnicity
American Indian/Alaska Native	216	—	200	—	173	—	205	—	201	—
Asian	932	—	933	—	872	—	746	—	637	—
Black/African American	16,805	—	16,283	—	15,794	—	15,508	—	12,859	—
Hispanic/Latino^d	10,636	—	10,387	—	10,388	—	10,287	—	8,294	—
Native Hawaiian/other Pacific Islander	43	—	52	—	63	—	70	—	66	—
White	9,887	—	9,648	—	9,451	—	9,075	—	7,843	—
Multiracial	1,583	—	1,378	—	1,214	—	1,106	—	792	—
Transmission category^e
Male sex at birth (≥13 yrs at diagnosis)^f
Male-to-male sexual contact	26,244	—	25,580	—	24,810	—	24,204	—	20,758	—
Injection drug use	1,225	—	1,326	—	1,431	—	1,406	—	1,198	—
Male-to-male sexual contact and injection drug use	1,551	—	1,483	—	1,477	—	1,536	—	1,109	—
Heterosexual contact^g	3,353	—	2,987	—	2,947	—	2,734	—	2,051	—
Perinatal^h	10	—	14	—	16	—	20	—	9	—
Otherⁱ	15	—	17	—	21	—	19	—	20	—
Subtotal	32,397	24.2	31,407	23.3	30,701	22.6	29,920	21.9	25,145	18.3
Female sex at birth (≥13 yrs at diagnosis)^f
Injection drug use	1,046	—	1,095	—	1,107	—	1,160	—	857	—
Heterosexual contact^g	6,473	—	6,216	—	6,008	—	5,805	—	4,575	—
Perinatal^h	48	—	51	—	46	—	47	—	51	—
Otherⁱ	8	—	7	—	7	—	7	—	7	—
Subtotal	7,575	5.4	7,369	5.2	7,167	5.1	7,020	4.9	5,490	3.8
Child (<13 yrs at diagnosis)
Perinatal	107	—	88	—	68	—	46	—	44	—
Otherⁱ	23	—	17	—	19	—	11	—	13	—
Subtotal	130	0.2	105	0.2	87	0.2	57	0.1	57	0.1
Region of residence^j
Northeast	6,211	11.1	5,987	10.7	5,565	9.9	5,312	9.5	4,271	7.6
Midwest	5,172	7.6	5,115	7.5	4,940	7.2	4,748	6.9	4,127	6.0
South	20,274	16.6	19,725	16.0	19,412	15.6	19,181	15.3	15,689	12.4
West	7,895	10.3	7,594	9.8	7,587	9.7	7,344	9.4	6,316	8.0
U.S. dependent areas	550	14.4	460	12.4	451	12.6	412	11.5	289	8.1
Total	40,102	12.3	38,881	11.8	37,955	11.5	36,997	11.1	30,692	9.2

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fData include transgender and additional gender identity persons.
^gSexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
ⁱOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^jData are based on residence at time of diagnosis of HIV infection.

Table 2a. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States
	American Indian/Alaska Native		Asian		Black/African American		Hispanic/Latino^a		Native Hawaiian/other Pacific Islander		White		Multiracial		Total
	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b	No.	Rate^b
Gender
Male	149	—	532	—	9,558	—	6,885	—	48	—	6,471	—	626	—	24,269	—
Female	44	—	88	—	2,970	—	907	—	15	—	1,281	—	134	—	5,439	—
Transgender woman/girl^c	8	—	16	—	309	—	202	—	3	—	72	—	28	—	638	—
Transgender man/boy^c	0	—	0	—	11	—	10	—	0	—	15	—	4	—	40	—
Additional gender identity^d	0	—	1	—	8	—	4	—	0	—	4	—	0	—	17	—
Age at diagnosis (yr)
<13	1	0.2	2	0.1	32	0.4	9	0.1	1	0.9	12	0.0	0	0.0	57	0.1
13–14	0	0.0	0	0.0	8	0.7	4	0.2	0	0.0	0	0.0	0	0.0	12	0.1
15–19	5	2.8	19	1.7	735	25.7	294	5.8	4	9.6	149	1.4	42	5.4	1,248	6.0
20–24	28	15.4	68	5.5	2,544	83.7	1,231	25.1	8	18.6	792	6.9	151	21.8	4,822	22.3
25–29	36	18.2	144	9.4	2,646	77.0	1,707	34.4	15	30.2	1,336	10.7	177	29.1	6,061	26.1
30–34	35	19.3	111	6.6	2,159	68.3	1,447	31.0	10	18.7	1,323	10.5	112	23.9	5,197	22.8
35–39	30	18.7	72	4.4	1,232	44.1	996	22.1	10	20.0	976	7.9	93	24.1	3,409	15.6
40–44	25	17.2	55	3.8	882	33.9	745	17.6	6	14.0	734	6.4	68	21.0	2,515	12.4
45–49	11	7.8	58	4.1	737	29.2	524	13.6	4	10.6	682	5.8	56	20.2	2,072	10.4
50–54	16	11.2	41	3.3	640	25.4	466	13.8	3	8.4	656	5.1	35	14.3	1,857	9.1
55–59	7	4.5	24	2.1	602	23.2	298	10.2	3	8.6	615	4.2	26	11.1	1,575	7.3
60–64	4	2.8	22	2.2	363	15.2	173	7.4	2	6.6	301	2.1	20	9.5	885	4.3
≥65	3	0.9	21	0.8	276	5.3	114	2.3	0	0.0	267	0.6	12	2.6	693	1.2
Transmission category^e
Male sex at birth (≥13 yrs at diagnosis)^f
Male-to-male sexual contact	126	—	491	—	8,062	—	6,176	—	42	—	5,126	—	550	—	20,572	—
Injection drug use	8	—	14	—	313	—	261	—	3	—	539	—	42	—	1,178	—
Male-to-male sexual contact and injection drug use	20	—	12	—	230	—	256	—	3	—	545	—	38	—	1,105	—
Heterosexual contact^g	3	—	30	—	1,240	—	390	—	2	—	325	—	24	—	2,012	—
Perinatal^h	0	—	0	—	8	—	0	—	0	—	1	—	0	—	9	—
Otherⁱ	0	—	2	—	8	—	3	—	0	—	6	—	0	—	20	—
Subtotal	157	16.0	549	7.1	9,859	60.9	7,086	29.4	50	19.9	6,542	7.8	654	26.8	24,897	18.3
Female sex at birth (≥13 yrs at diagnosis)
Injection drug use	20	—	6	—	250	—	134	—	2	—	422	—	21	—	855	—
Heterosexual contact^g	23	—	79	—	2,674	—	773	—	12	—	858	—	116	—	4,536	—
Perinatal^h	0	—	1	—	40	—	5	—	0	—	5	—	1	—	51	—
Otherⁱ	0	—	1	—	1	—	1	—	0	—	4	—	0	—	7	—
Subtotal	43	4.2	86	1.0	2,965	16.4	913	3.8	15	6.0	1,289	1.5	138	5.3	5,449	3.8
Child (<13 yrs at diagnosis)
Perinatal	0	—	0	—	26	—	8	—	1	—	9	—	0	—	44	—
Otherⁱ	1	—	2	—	6	—	1	—	0	—	3	—	0	—	13	—
Subtotal	1	0.2	2	0.1	32	0.4	9	0.1	1	0.9	12	0.0	0	0.0	57	0.1
Region of residence^j
Northeast	7	5.4	93	2.4	1,721	27.2	1,340	16.0	4	17.7	972	2.7	134	13.2	4,271	7.6
Midwest	32	7.7	75	3.1	1,980	27.5	515	9.1	5	12.9	1,396	2.7	124	8.6	4,127	6.0
South	49	6.0	151	3.2	8,081	33.3	3,435	14.6	13	12.9	3,566	5.0	394	15.6	15,689	12.4
West	113	10.5	318	3.8	1,074	29.6	2,718	11.4	44	9.8	1,909	4.9	140	5.5	6,316	8.0
Total	201	8.3	637	3.3	12,856	31.0	8,008	13.1	66	10.8	7,843	4.0	792	10.5	30,403	9.2

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aHispanic/Latino persons can be of any race.
^bRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^c“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^dAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fData presented include transgender and additional gender identity persons.
^gSexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
ⁱOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^jData are based on residence at time of diagnosis of HIV infection.

Table 2b. Diagnoses of HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
	American Indian/Alaska Native	Asian	Black/African American	Hispanic/Latino^a	Native Hawaiian/other Pacific Islander	White	Multiracial	Total
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	149	532	9,561	7,128	48	6,471	626	24,515
Female	44	88	2,970	948	15	1,281	134	5,480
Transgender woman/girl^b	8	16	309	204	3	72	28	640
Transgender man/boy^b	0	0	11	10	0	15	4	40
Additional gender identity^c	0	1	8	4	0	4	0	17
Age at diagnosis (yr)
<13	1	2	32	9	1	12	0	57
13–14	0	0	8	4	0	0	0	12
15–19	5	19	737	300	4	149	42	1,256
20–24	28	68	2,544	1,276	8	792	151	4,867
25–29	36	144	2,646	1,749	15	1,336	177	6,103
30–34	35	111	2,160	1,482	10	1,323	112	5,233
35–39	30	72	1,232	1,032	10	976	93	3,445
40–44	25	55	882	770	6	734	68	2,540
45–49	11	58	737	546	4	682	56	2,094
50–54	16	41	640	492	3	656	35	1,883
55–59	7	24	602	322	3	615	26	1,599
60–64	4	22	363	189	2	301	20	901
≥65	3	21	276	123	0	267	12	702
Transmission category^d
Male sex at birth (≥13 yrs at diagnosis)^e
Male-to-male sexual contact	126	491	8,064	6,359	42	5,126	550	20,758
Injection drug use	8	14	313	280	3	539	42	1,198
Male-to-male sexual contact and injection drug use	20	12	230	261	3	545	38	1,109
Heterosexual contact^f	3	30	1,241	427	2	325	24	2,051
Perinatal^g	0	0	8	0	0	1	0	9
Other^h	0	2	8	3	0	6	0	20
Subtotal	157	549	9,862	7,331	50	6,542	654	25,145
Female sex at birth (≥13 yrs at diagnosis)^e
Injection drug use	20	6	250	136	2	422	21	857
Heterosexual contact^f	23	79	2,674	812	12	858	116	4,575
Perinatal^g	0	1	40	5	0	5	1	51
Other^h	0	1	1	1	0	4	0	7
Subtotal	43	86	2,965	954	15	1,289	138	5,490
Child (<13 yrs at diagnosis)
Perinatal	0	0	26	8	1	9	0	44
Other^h	1	2	6	1	0	3	0	13
Subtotal	1	2	32	9	1	12	0	57
Region of residence^f
Northeast	7	93	1,721	1,340	4	972	134	4,271
Midwest	32	75	1,980	515	5	1,396	124	4,127
South	49	151	8,081	3,435	13	3,566	394	15,689
West	113	318	1,074	2,718	44	1,909	140	6,316
U.S. dependent areas	0	0	3	286	0	0	0	289
Total	201	637	12,859	8,294	66	7,843	792	30,692

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aHispanic/Latino persons can be of any race.
^b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^eData include transgender and additional gender identity persons.
^fSexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱData are based on residence at time of diagnosis of HIV infection.

Table 3a. Diagnoses of HIV infection among persons aged ≥13 years, by year of diagnosis, sex assigned at birth, and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at diagnosis (yr)
13–14	10	0.2	13	0.3	11	0.3	12	0.3	6	0.1
15–19	1,467	13.6	1,536	14.2	1,476	13.7	1,444	13.4	1,091	10.2
20–24	6,173	53.7	5,691	50.3	5,389	48.2	5,242	47.4	4,264	38.6
25–29	6,898	59.1	6,745	56.7	6,759	56.3	6,455	53.7	5,288	44.5
30–34	4,608	41.9	4,659	42.0	4,719	42.2	4,713	41.4	4,386	37.9
35–39	3,249	31.3	3,339	31.5	3,282	30.4	3,235	29.7	2,708	24.8
40–44	2,475	25.3	2,238	23.0	2,185	22.3	2,218	22.4	1,947	19.3
45–49	2,273	21.9	2,165	20.9	2,058	20.1	1,897	18.8	1,521	15.4
50–54	2,133	19.9	1,979	18.9	1,796	17.5	1,685	16.7	1,400	13.9
55–59	1,308	12.3	1,313	12.3	1,299	12.2	1,321	12.4	1,155	11.0
60–64	734	7.9	751	7.9	723	7.4	757	7.7	616	6.2
≥65	624	2.9	612	2.7	634	2.7	610	2.5	515	2.1
Race/ethnicity
American Indian/Alaska Native	175	18.5	155	16.2	144	14.9	159	16.3	157	16.0
Asian	776	10.9	806	11.0	759	10.1	637	8.3	549	7.1
Black/African American	12,345	79.3	11,944	75.9	11,718	73.7	11,604	72.3	9,859	60.9
Hispanic/Latino^c	8,890	40.2	8,750	38.6	8,747	37.8	8,708	36.9	7,086	29.4
Native Hawaiian/other Pacific Islander	32	13.8	43	18.1	56	23.1	57	23.1	50	19.9
White	8,438	10.0	8,203	9.8	7,958	9.5	7,550	9.0	6,542	7.8
Multiracial	1,296	60.9	1,140	51.7	949	41.6	874	37.0	654	26.8
Region of residence^d
Northeast	4,805	20.8	4,648	20.1	4,337	18.8	4,157	18.0	3,372	14.6
Midwest	4,202	15.1	4,149	14.8	4,004	14.3	3,776	13.4	3,382	12.0
South	16,081	32.4	15,591	31.1	15,411	30.4	15,304	29.9	12,650	24.5
West	6,864	21.7	6,653	20.8	6,579	20.4	6,352	19.5	5,493	16.7
Subtotal	31,952	24.2	31,041	23.3	30,331	22.6	29,589	21.9	24,897	18.3
Female sex at birth^b
Age at diagnosis (yr)
13–14	16	0.4	12	0.3	9	0.2	9	0.2	6	0.1
15–19	248	2.4	250	2.4	243	2.4	204	2.0	157	1.5
20–24	742	6.8	775	7.2	720	6.8	727	6.9	558	5.3
25–29	1,049	9.3	978	8.5	952	8.3	947	8.2	773	6.8
30–34	1,033	9.5	1,013	9.3	954	8.7	960	8.7	811	7.2
35–39	961	9.2	921	8.7	927	8.6	905	8.3	701	6.4
40–44	770	7.8	742	7.5	786	7.9	756	7.5	568	5.6
45–49	773	7.3	765	7.3	722	6.9	678	6.6	551	5.5
50–54	723	6.5	658	6.1	659	6.2	627	6.0	457	4.4
55–59	574	5.1	559	5.0	544	4.8	511	4.5	420	3.8
60–64	346	3.4	332	3.2	323	3.1	350	3.3	269	2.5
≥65	235	0.9	270	1.0	247	0.8	265	0.9	178	0.6
Race/ethnicity
American Indian/Alaska Native	41	4.1	45	4.5	29	2.9	45	4.4	43	4.2
Asian	147	1.8	117	1.4	103	1.2	96	1.1	86	1.0
Black/African American	4,378	25.1	4,279	24.3	4,018	22.6	3,867	21.6	2,965	16.4
Hispanic/Latino^c	1,193	5.5	1,175	5.3	1,198	5.2	1,181	5.1	913	3.8
Native Hawaiian/other Pacific Islander	6	2.6	7	3.0	5	2.1	9	3.7	15	6.0
White	1,427	1.6	1,425	1.6	1,475	1.7	1,513	1.7	1,289	1.5
Multiracial	278	12.2	227	9.7	258	10.6	228	9.1	138	5.3
Region of residence^d
Northeast	1,393	5.6	1,329	5.4	1,220	4.9	1,148	4.6	890	3.6
Midwest	939	3.2	947	3.3	923	3.2	964	3.3	736	2.5
South	4,128	7.9	4,071	7.7	3,953	7.4	3,845	7.1	3,011	5.5
West	1,010	3.1	928	2.9	990	3.0	982	3.0	812	2.4
Subtotal	7,470	5.4	7,275	5.2	7,086	5.1	6,939	4.9	5,449	3.8
Total	39,422	14.6	38,316	14.1	37,417	13.6	36,528	13.2	30,346	10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population.
^bData include transgender and additional gender identity persons.
^cHispanic/Latino persons can be of any race.
^dData are based on residence at time of diagnosis of HIV infection.

Table 3b. Diagnoses of HIV infection among persons aged ≥13 years, by year of diagnosis, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at diagnosis (yr)
13–14	10	0.2	13	0.3	11	0.3	12	0.3	6	0.1
15–19	1,475	13.5	1,544	14.1	1,491	13.7	1,450	13.3	1,099	10.2
20–24	6,240	53.7	5,752	50.2	5,442	48.2	5,294	47.3	4,305	38.6
25–29	6,963	59.0	6,797	56.5	6,829	56.3	6,508	53.6	5,327	44.4
30–34	4,664	42.0	4,714	42.1	4,771	42.3	4,761	41.5	4,421	37.9
35–39	3,302	31.5	3,379	31.6	3,311	30.4	3,269	29.7	2,741	24.8
40–44	2,516	25.5	2,266	23.1	2,218	22.4	2,244	22.4	1,966	19.3
45–49	2,317	22.1	2,191	20.9	2,088	20.2	1,924	18.9	1,538	15.4
50–54	2,169	20.0	2,017	19.0	1,834	17.7	1,708	16.8	1,420	14.0
55–59	1,342	12.5	1,336	12.4	1,319	12.2	1,345	12.5	1,172	11.0
60–64	753	8.0	769	8.0	738	7.5	776	7.8	629	6.2
≥65	646	2.9	629	2.8	649	2.8	629	2.6	521	2.1
Race/ethnicity
American Indian/Alaska Native	175	—	155	—	144	—	159	—	157	—
Asian	777	—	809	—	763	—	644	—	549	—
Black/African American	12,351	—	11,946	—	11,726	—	11,608	—	9,862	—
Hispanic/Latino^c	9,320	—	9,106	—	9,098	—	9,020	—	7,331	—
Native Hawaiian/other Pacific Islander	37	—	44	—	58	—	60	—	50	—
White	8,440	—	8,206	—	7,961	—	7,555	—	6,542	—
Multiracial	1,297	—	1,141	—	951	—	874	—	654	—
Region of residence^d
Northeast	4,805	20.8	4,648	20.1	4,337	18.8	4,157	18.0	3,372	14.6
Midwest	4,202	15.1	4,149	14.8	4,004	14.3	3,776	13.4	3,382	12.0
South	16,081	32.4	15,591	31.1	15,411	30.4	15,304	29.9	12,650	24.5
West	6,864	21.7	6,653	20.8	6,579	20.4	6,352	19.5	5,493	16.7
U.S. dependent areas	445	29.0	366	24.2	370	25.1	331	22.4	248	16.9
Subtotal	32,397	24.2	31,407	23.3	30,701	22.6	29,920	21.9	25,145	18.3
Female sex at birth^b
Age at diagnosis (yr)
13–14	16	0.4	12	0.3	9	0.2	9	0.2	6	0.1
15–19	250	2.4	254	2.4	245	2.3	204	2.0	157	1.5
20–24	748	6.8	780	7.2	729	6.8	732	6.8	562	5.3
25–29	1,055	9.3	989	8.5	959	8.2	953	8.2	776	6.8
30–34	1,042	9.5	1,020	9.3	960	8.7	969	8.7	812	7.1
35–39	978	9.3	933	8.7	932	8.6	910	8.3	704	6.4
40–44	786	7.8	749	7.5	794	7.9	769	7.6	574	5.6
45–49	788	7.4	780	7.3	736	7.0	688	6.6	556	5.4
50–54	732	6.5	670	6.1	670	6.2	634	6.0	463	4.4
55–59	588	5.2	571	5.0	552	4.8	524	4.6	427	3.8
60–64	354	3.4	337	3.2	328	3.1	355	3.3	272	2.5
≥65	238	0.9	274	1.0	253	0.9	273	0.9	181	0.6
Race/ethnicity
American Indian/Alaska Native	41	—	45	—	29	—	45	—	43	—
Asian	147	—	117	—	103	—	96	—	86	—
Black/African American	4,378	—	4,281	—	4,018	—	3,868	—	2,965	—
Hispanic/Latino^c	1,298	—	1,265	—	1,279	—	1,260	—	954	—
Native Hawaiian/other Pacific Islander	6	—	7	—	5	—	10	—	15	—
White	1,427	—	1,427	—	1,475	—	1,513	—	1,289	—
Multiracial	278	—	227	—	258	—	228	—	138	—
Region of residence^d
Northeast	1,393	5.6	1,329	5.4	1,220	4.9	1,148	4.6	890	3.6
Midwest	939	3.2	947	3.3	923	3.2	964	3.3	736	2.5
South	4,128	7.9	4,071	7.7	3,953	7.4	3,845	7.1	3,011	5.5
West	1,010	3.1	928	2.9	990	3.0	982	3.0	812	2.4
U.S. dependent areas	105	6.1	94	5.6	81	5.0	81	4.9	41	2.5
Subtotal	7,575	5.4	7,369	5.2	7,167	5.1	7,020	4.9	5,490	3.8
Total	39,972	14.6	38,776	14.1	37,868	13.7	36,940	13.2	30,635	10.9

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^bData include transgender and additional gender identity persons.
^cHispanic/Latino persons can be of any race.
^dData are based on residence at time of diagnosis of HIV infection.

Table 4a. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥13 years, by year of diagnosis and selected characteristics, 2016–2020—United States
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	61	57	41	40	31
20–24	201	149	163	166	145
25–29	185	171	185	165	193
30–34	90	109	95	130	125
35–39	69	55	72	62	47
40–44	27	30	32	40	37
45–49	17	21	22	21	31
50–54	9	8	7	16	16
55–59	9	7	6	7	7
60–64	3	5	2	4	5
≥65	3	0	2	1	1
Race/ethnicity
American Indian/Alaska Native	4	2	9	5	8
Asian	8	18	9	11	16
Black/African American	343	306	302	315	309
Hispanic/Latino^b	212	184	211	215	202
Native Hawaiian/other Pacific Islander	2	3	3	5	3
White	61	76	63	80	72
Multiracial	44	23	30	21	28
Exposure category^c
Sexual contact^d	620	555	563	580	576
Injection drug use	0	3	4	2	1
Sexual contact^d and injection drug use	40	38	50	54	35
Other^e	14	16	10	16	26
Region of residence^f
Northeast	144	102	114	104	105
Midwest	99	99	98	85	98
South	302	278	272	287	279
West	129	133	143	176	156
Subtotal	674	612	627	652	638
Transgender man^a
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	3	2	0	1
20–24	5	7	9	11	12
25–29	5	16	18	18	10
30–34	4	1	9	12	8
35–39	3	3	4	2	5
40–44	1	0	4	0	2
45–49	2	2	1	2	1
50–54	1	0	1	0	1
55–59	0	1	0	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian	1	2	0	1	0
Black/African American	5	11	18	18	11
Hispanic/Latino^b	7	6	10	12	10
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	6	11	18	10	15
Multiracial	3	3	2	4	4
Exposure category^c
Sexual contact^d	20	28	40	36	29
Injection drug use	0	1	2	1	1
Sexual contact^d and injection drug use	1	1	2	2	5
Other^e	1	3	4	6	5
Region of residence^f
Northeast	2	5	7	6	8
Midwest	5	8	7	6	2
South	6	12	16	17	24
West	9	8	18	16	6
Subtotal	22	33	48	45	40
Additional gender identity^g
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	1	4	3	1
20–24	4	2	5	8	7
25–29	4	3	4	6	6
30–34	1	3	1	3	1
35–39	0	4	1	2	2
40–44	0	0	0	0	0
45–49	0	2	0	0	0
50–54	0	0	0	1	0
55–59	1	0	0	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	1	0	0
Asian	0	1	2	0	1
Black/African American	5	6	5	8	8
Hispanic/Latino^b	3	5	2	6	4
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	2	3	3	5	4
Multiracial	1	0	2	4	0
Exposure category^c
Sexual contact^d	9	14	15	21	14
Injection drug use	0	0	0	0	0
Sexual contact^d and injection drug use	2	0	0	1	1
Other^e	0	1	0	1	2
Region of residence^f
Northeast	4	9	10	8	2
Midwest	1	2	0	7	5
South	4	4	3	4	5
West	2	0	2	4	5
Subtotal	11	15	15	23	17
Total	707	660	690	720	695

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Additional gender identity not included due to small numbers. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bHispanic/Latino persons can be of any race.
^cRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^dFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^eOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^fData are based on residence at time of diagnosis of HIV infection.
^gAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 4b. Diagnoses of HIV infection among transgender and additional gender identity persons aged ≥13 years, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	61	57	41	40	31
20–24	202	150	164	167	146
25–29	186	172	186	166	193
30–34	91	109	95	130	126
35–39	69	55	72	62	47
40–44	27	30	32	40	37
45–49	17	21	22	21	31
50–54	9	8	7	16	16
55–59	9	7	6	7	7
60–64	3	5	2	4	5
≥65	3	0	2	1	1
Race/ethnicity
American Indian/Alaska Native	4	2	9	5	8
Asian	8	18	9	11	16
Black/African American	343	306	302	315	309
Hispanic/Latino^b	215	186	213	217	204
Native Hawaiian/other Pacific Islander	2	3	3	5	3
White	61	76	63	80	72
Multiracial	44	23	30	21	28
Exposure category^c
Sexual contact^d	623	557	565	582	578
Injection drug use	0	3	4	2	1
Sexual contact^d and injection drug use	40	38	50	54	35
Other^e	14	16	10	16	26
Region of residence^f
Northeast	144	102	114	104	105
Midwest	99	99	98	85	98
South	302	278	272	287	279
West	129	133	143	176	156
US dependent areas	3	2	2	2	2
Subtotal	677	614	629	654	640
Transgender man^a
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	3	2	0	1
20–24	5	7	9	11	12
25–29	5	16	18	18	10
30–34	4	1	9	12	8
35–39	3	3	5	2	5
40–44	1	0	4	0	2
45–49	2	2	1	2	1
50–54	1	0	1	0	1
55–59	0	1	0	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian	1	2	0	1	0
Black/African American	5	11	18	18	11
Hispanic/Latino^b	7	6	11	12	10
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	6	11	18	10	15
Multiracial	3	3	2	4	4
Exposure category^c
Sexual contact^d	20	28	41	36	29
Injection drug use	0	1	2	1	1
Sexual contact^d and injection drug use	1	1	2	2	5
Other^e	1	3	4	6	5
Region of residence^f
Northeast	2	5	7	6	8
Midwest	5	8	7	6	2
South	6	12	16	17	24
West	9	8	18	16	6
US dependent areas	0	0	1	0	0
Subtotal	22	33	49	45	40
Additional gender identity^g
Age at diagnosis (yr)
13–14	0	0	0	0	0
15–19	1	1	4	3	1
20–24	4	2	5	8	7
25–29	4	3	4	6	6
30–34	1	3	1	3	1
35–39	0	4	1	2	2
40–44	0	0	0	0	0
45–49	0	2	0	0	0
50–54	0	0	0	1	0
55–59	1	0	0	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	1	0	0
Asian	0	1	2	0	1
Black/African American	5	6	5	8	8
Hispanic/Latino^b	3	5	2	6	4
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	2	3	3	5	4
Multiracial	1	0	2	4	0
Exposure category^c
Sexual contact^d	9	14	15	21	14
Injection drug use	0	0	0	0	0
Sexual contact^d and injection drug use	2	0	0	1	1
Other^e	0	1	0	1	2
Region of residence^f
Northeast	4	9	10	8	2
Midwest	1	2	0	7	5
South	4	4	3	4	5
West	2	0	2	4	5
US dependent areas	0	0	0	0	0
Subtotal	11	15	15	23	17
Total	710	662	693	722	697

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Additional gender identity not included due to small numbers. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bHispanic/Latino persons can be of any race.
^cRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^dFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^eOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^fData are based on residence at time of diagnosis of HIV infection.
^gAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 5a. Diagnoses of HIV infection among males, based on sex assigned at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States
	Male-to-male sexual contact					Male-to-male sexual contact and injection drug use
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	2	2	7	7	5	0	0	0	0	0
20–24	24	18	25	25	23	4	3	2	3	4
25–29	36	31	21	28	25	5	5	7	6	4
30–34	28	18	18	16	20	3	6	6	1	3
35–39	12	14	9	19	14	2	1	2	3	5
40–44	14	11	7	6	14	0	2	1	0	3
45–49	6	6	7	7	7	0	1	2	1	1
50–54	5	8	7	9	10	1	0	0	1	1
55–59	3	2	3	3	5	0	0	0	0	0
60–64	3	2	0	2	2	0	1	0	0	0
≥65	1	1	3	0	1	0	1	0	0	0
Region of residence^a
Northeast	7	2	5	4	6	0	0	0	0	0
Midwest	12	10	13	8	11	1	3	5	2	4
South	33	26	17	41	35	6	9	4	3	0
West	82	75	72	67	74	9	7	13	11	16
Total	135	112	106	120	126	16	20	21	16	20
Asian
Age at diagnosis (yr)
13–14	0	0	1	0	0	0	0	0	0	0
15–19	20	25	24	18	17	0	0	0	0	0
20–24	109	148	108	91	64	4	3	1	2	1
25–29	155	151	168	131	124	2	4	3	2	4
30–34	123	113	119	94	89	2	5	3	6	4
35–39	78	90	74	74	52	1	0	3	2	0
40–44	86	74	62	43	44	1	1	1	0	2
45–49	50	65	58	51	42	1	3	0	1	1
50–54	31	35	24	35	25	1	0	0	0	0
55–59	19	20	19	18	14	0	0	0	0	0
60–64	8	8	9	7	12	0	0	0	0	0
≥65	10	7	10	9	8	1	0	0	0	0
Region of residence^a
Northeast	134	129	130	105	73	3	3	2	2	0
Midwest	59	76	66	53	57	4	0	0	1	1
South	147	153	173	145	110	1	1	1	4	1
West	348	379	306	268	251	6	12	10	7	10
Total	689	737	675	570	491	13	16	13	14	12
Black/African American
Age at diagnosis (yr)
13–14	4	4	7	7	2	0	0	0	0	0
15–19	802	855	811	802	608	16	13	10	10	10
20–24	2,815	2,530	2,425	2,399	2,076	65	43	51	39	42
25–29	2,544	2,492	2,513	2,353	1,982	78	71	78	88	56
30–34	1,210	1,330	1,274	1,425	1,466	50	49	49	66	55
35–39	721	761	744	744	670	32	37	27	40	22
40–44	447	442	448	469	397	16	17	20	23	15
45–49	377	356	354	339	269	20	12	10	18	11
50–54	346	321	309	281	244	13	24	18	17	9
55–59	202	206	200	212	203	9	12	10	8	6
60–64	98	111	101	114	92	7	5	5	6	2
≥65	64	67	79	80	55	4	5	4	2	2
Region of residence^a
Northeast	1,144	1,143	1,082	1,108	941	38	36	50	41	36
Midwest	1,584	1,502	1,461	1,415	1,323	66	51	52	46	41
South	6,064	6,013	5,892	5,899	5,079	167	150	137	175	115
West	839	819	829	803	719	40	51	44	55	37
Total	9,630	9,476	9,264	9,226	8,062	311	288	282	318	230
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	2	5	0	2	3	0	0	0	0	0
15–19	314	337	320	356	252	17	11	10	7	5
20–24	1,486	1,382	1,375	1,382	1,047	80	68	73	64	33
25–29	1,796	1,750	1,791	1,752	1,434	85	98	105	96	70
30–34	1,325	1,332	1,321	1,312	1,187	77	68	54	71	55
35–39	934	927	914	926	735	47	50	44	62	32
40–44	624	594	557	611	537	37	22	27	34	20
45–49	475	513	501	458	358	12	18	19	22	19
50–54	356	342	335	348	294	17	16	16	21	11
55–59	154	172	197	182	191	7	8	3	10	4
60–64	76	71	90	92	85	4	3	4	2	7
≥65	54	74	69	70	54	3	2	2	3	1
Region of residence^a
Northeast	1,247	1,285	1,172	1,163	924	56	40	54	60	26
Midwest	494	517	521	521	412	30	30	27	35	17
South	3,253	3,199	3,220	3,247	2,642	146	132	112	142	90
West	2,602	2,498	2,557	2,562	2,199	155	164	166	156	123
Total	7,596	7,499	7,469	7,492	6,176	386	365	359	394	256
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	1	3	1	3	0	0	0	0	0
20–24	1	9	7	6	6	0	0	2	0	0
25–29	7	9	9	19	11	2	0	2	0	1
30–34	3	9	11	10	7	2	0	1	1	1
35–39	7	2	8	7	7	0	1	0	1	0
40–44	3	5	2	4	5	0	0	0	0	0
45–49	0	1	2	0	1	0	0	0	0	1
50–54	2	1	1	4	2	0	0	0	0	0
55–59	0	0	4	1	1	0	0	0	0	0
60–64	0	0	1	1	0	0	0	0	0	0
≥65	1	0	1	0	0	1	0	0	0	0
Region of residence^a
Northeast	2	3	2	2	3	1	0	0	0	0
Midwest	1	2	2	5	3	0	0	0	0	1
South	4	7	8	13	8	0	0	0	0	0
West	18	25	36	33	28	4	1	5	2	2
Total	24	37	48	52	42	5	1	5	3	3
White
Age at diagnosis (yr)
13–14	0	1	0	1	0	0	0	0	0	0
15–19	155	161	169	132	120	20	13	10	14	1
20–24	868	916	798	730	591	95	87	70	74	48
25–29	1,206	1,204	1,124	1,096	913	160	169	181	166	124
30–34	962	885	948	888	858	129	130	145	144	106
35–39	673	726	658	662	544	86	100	115	112	103
40–44	612	490	523	455	454	67	62	57	64	52
45–49	709	614	562	467	406	58	60	49	52	42
50–54	733	672	535	503	441	44	41	43	36	32
55–59	459	440	432	458	410	35	25	27	31	23
60–64	239	243	250	235	204	14	16	7	14	9
≥65	200	185	208	182	185	9	10	6	10	5
Region of residence^a
Northeast	953	831	749	693	583	66	81	76	61	73
Midwest	1,183	1,216	1,086	968	937	141	107	133	145	99
South	2,968	2,837	2,794	2,657	2,282	280	310	285	294	206
West	1,712	1,655	1,580	1,490	1,325	229	213	217	215	166
Total	6,815	6,538	6,208	5,808	5,126	716	712	711	715	545
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	57	57	43	45	34	3	2	3	2	1
20–24	276	221	183	154	115	18	12	9	6	6
25–29	265	245	197	175	134	25	11	25	17	10
30–34	150	144	119	118	77	16	11	13	24	4
35–39	79	81	83	73	62	9	13	12	5	6
40–44	69	55	44	46	43	3	4	2	7	5
45–49	57	49	40	31	34	7	6	6	1	5
50–54	44	52	31	17	24	5	6	4	2	1
55–59	33	21	14	32	13	3	3	0	2	0
60–64	20	15	10	9	7	3	0	0	0	0
≥65	9	8	11	7	9	0	0	0	1	0
Region of residence^a
Northeast	205	167	136	138	94	16	10	7	7	5
Midwest	142	151	112	77	83	18	10	14	13	7
South	497	451	370	363	266	36	35	29	31	16
West	216	178	157	127	106	22	14	23	15	11
Total	1,059	947	775	706	550	92	69	73	66	38
Total
Age at diagnosis (yr)
13–14	5	10	8	10	5	0	0	0	0	0
15–19	1,351	1,439	1,376	1,359	1,038	55	39	32	33	17
20–24	5,579	5,224	4,920	4,787	3,921	265	215	208	189	134
25–29	6,010	5,881	5,823	5,553	4,622	357	359	402	375	269
30–34	3,801	3,831	3,810	3,863	3,704	279	269	271	312	227
35–39	2,504	2,600	2,490	2,505	2,083	177	201	204	224	169
40–44	1,854	1,670	1,643	1,634	1,494	125	108	108	128	96
45–49	1,674	1,605	1,522	1,353	1,116	99	100	87	96	79
50–54	1,517	1,432	1,242	1,196	1,040	82	87	82	77	54
55–59	870	862	869	905	836	54	49	41	50	33
60–64	444	451	460	460	401	29	25	18	23	19
≥65	339	342	380	349	312	18	18	13	17	8
Region of residence^a
Northeast	3,691	3,559	3,274	3,213	2,624	178	170	188	172	141
Midwest	3,475	3,474	3,261	3,047	2,826	260	201	232	242	171
South	12,966	12,684	12,473	12,364	10,420	636	637	567	650	428
West	5,816	5,629	5,537	5,350	4,702	465	462	478	461	365
Total	25,948	25,346	24,545	23,974	20,572	1,539	1,470	1,465	1,524	1,105

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

^a Data are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 5b. Diagnoses of HIV infection among males, based on sex assigned at birth, attributed to male-to-male sexual contact and male-to-male sexual contact and injection drug use, by year of diagnosis and selected characteristics, 2016–2020—United States and 6 dependent areas
	Male-to-male sexual contact					Male-to-male sexual contact and injection drug use
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	2	2	7	7	5	0	0	0	0	0
20–24	24	18	25	25	23	4	3	2	3	4
25–29	36	31	21	28	25	5	5	7	6	4
30–34	28	18	18	16	20	3	6	6	1	3
35–39	12	14	9	19	14	2	1	2	3	5
40–44	14	11	7	6	14	0	2	1	0	3
45–49	6	6	7	7	7	0	1	2	1	1
50–54	5	8	7	9	10	1	0	0	1	1
55–59	3	2	3	3	5	0	0	0	0	0
60–64	3	2	0	2	2	0	1	0	0	0
≥65	1	1	3	0	1	0	1	0	0	0
Region of residence^a
Northeast	7	2	5	4	6	0	0	0	0	0
Midwest	12	10	13	8	11	1	3	5	2	4
South	33	26	17	41	35	6	9	4	3	0
West	82	75	72	67	74	9	7	13	11	16
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	135	112	106	120	126	16	20	21	16	20
Asian
Age at diagnosis (yr)
13–14	0	0	1	0	0	0	0	0	0	0
15–19	20	25	24	18	17	0	0	0	0	0
20–24	109	148	108	91	64	4	3	1	2	1
25–29	155	151	169	134	124	2	4	3	3	4
30–34	123	115	121	95	89	2	5	3	6	4
35–39	79	91	74	75	52	1	0	3	2	0
40–44	86	74	62	43	44	1	1	1	0	2
45–49	50	65	58	51	42	1	3	0	1	1
50–54	31	35	24	35	25	1	0	0	1	0
55–59	19	20	19	18	14	0	0	0	0	0
60–64	8	8	9	7	12	0	0	0	0	0
≥65	10	7	10	9	8	1	0	0	0	0
Region of residence^a
Northeast	134	129	130	105	73	3	3	2	2	0
Midwest	59	76	66	53	57	4	0	0	1	1
South	147	153	173	145	110	1	1	1	4	1
West	348	379	306	268	251	6	12	10	7	10
U.S. dependent areas	1	3	4	6	0	0	0	0	1	0
Total	690	740	679	576	491	13	16	13	15	12
Black/African American
Age at diagnosis (yr)
13–14	4	4	7	7	2	0	0	0	0	0
15–19	802	855	811	802	610	16	13	10	10	10
20–24	2,816	2,530	2,425	2,400	2,076	65	43	51	39	42
25–29	2,544	2,492	2,515	2,353	1,982	78	71	78	88	56
30–34	1,211	1,330	1,275	1,425	1,466	50	49	49	66	55
35–39	721	761	744	744	670	32	37	27	40	22
40–44	448	443	449	469	397	16	17	20	23	15
45–49	377	356	354	339	269	20	12	10	18	11
50–54	346	321	309	281	244	13	24	18	17	9
55–59	202	206	200	212	203	9	12	10	8	6
60–64	98	111	101	114	92	7	5	5	6	2
≥65	64	67	79	80	55	4	5	4	2	2
Region of residence^a
Northeast	1,144	1,143	1,082	1,108	941	38	36	50	41	36
Midwest	1,584	1,502	1,461	1,415	1,323	66	51	52	46	41
South	6,064	6,013	5,892	5,899	5,079	167	150	137	175	115
West	839	819	829	803	719	40	51	44	55	37
U.S. dependent areas	3	1	4	1	2	0	0	0	0	0
Total	9,633	9,478	9,268	9,227	8,064	311	288	282	318	230
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	2	5	0	2	3	0	0	0	0	0
15–19	321	344	334	362	258	18	11	10	7	5
20–24	1,547	1,432	1,425	1,426	1,085	80	70	74	67	34
25–29	1,853	1,792	1,844	1,796	1,467	87	102	108	97	72
30–34	1,367	1,369	1,356	1,349	1,217	79	70	57	73	55
35–39	970	948	934	950	761	50	52	45	64	34
40–44	644	609	579	624	547	38	23	28	35	20
45–49	495	529	523	471	370	13	21	19	22	19
50–54	379	364	351	363	310	17	16	17	21	11
55–59	169	181	207	193	197	7	8	5	11	4
60–64	78	75	97	101	89	4	3	5	2	7
≥65	56	76	72	73	56	3	2	3	4	1
Region of residence^a
Northeast	1,247	1,285	1,172	1,163	924	56	40	54	60	26
Midwest	494	517	521	521	412	30	30	27	35	17
South	3,253	3,199	3,220	3,247	2,642	146	132	112	142	90
West	2,602	2,498	2,557	2,562	2,199	155	164	166	156	123
U.S. dependent areas	285	226	253	217	183	11	13	12	10	5
Total	7,881	7,725	7,722	7,709	6,359	397	378	371	404	261
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	1	3	1	3	0	0	0	0	0
20–24	2	9	7	6	6	0	0	2	0	0
25–29	7	9	9	19	11	3	0	2	1	1
30–34	5	9	11	10	7	2	0	1	1	1
35–39	7	2	9	7	7	0	1	0	1	0
40–44	3	5	2	5	5	0	0	0	0	0
45–49	0	1	2	0	1	0	0	0	0	1
50–54	2	1	1	5	2	0	0	0	0	0
55–59	0	0	4	1	1	0	0	0	0	0
60–64	0	0	1	1	0	0	0	0	0	0
≥65	1	0	1	0	0	1	0	0	0	0
Region of residence^a
Northeast	2	3	2	2	3	1	0	0	0	0
Midwest	1	2	2	5	3	0	0	0	0	1
South	4	7	8	13	8	0	0	0	0	0
West	18	25	36	33	28	4	1	5	2	2
U.S. dependent areas	3	0	1	2	0	1	0	0	1	0
Total	28	37	49	54	42	6	1	5	4	3
White
Age at diagnosis (yr)
13–14	0	1	0	1	0	0	0	0	0	0
15–19	155	161	169	132	120	20	13	10	14	1
20–24	869	916	798	730	591	95	87	70	74	48
25–29	1,206	1,204	1,124	1,096	913	160	169	181	166	124
30–34	963	885	948	890	858	129	130	145	144	106
35–39	673	728	658	662	544	86	100	115	112	103
40–44	612	490	524	455	454	67	62	57	64	52
45–49	709	614	562	467	406	58	60	49	52	42
50–54	733	673	536	503	441	44	41	43	36	32
55–59	459	440	433	458	410	35	25	27	31	23
60–64	239	243	250	236	204	14	16	7	14	9
≥65	200	185	208	183	185	9	10	6	10	5
Region of residence^a
Northeast	953	831	749	693	583	66	81	76	61	73
Midwest	1,183	1,216	1,086	968	937	141	107	133	145	99
South	2,968	2,837	2,794	2,657	2,282	280	310	285	294	206
West	1,712	1,655	1,580	1,490	1,325	229	213	217	215	166
U.S. dependent areas	2	3	3	4	0	0	0	0	0	0
Total	6,817	6,541	6,211	5,812	5,126	716	712	711	715	545
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	57	57	43	45	34	3	2	3	2	1
20–24	276	221	183	154	115	18	12	9	6	6
25–29	265	245	197	175	134	25	11	25	17	10
30–34	150	144	119	118	77	16	11	13	24	4
35–39	79	81	83	73	62	9	13	12	5	6
40–44	69	55	44	46	43	3	4	2	7	5
45–49	57	49	40	31	34	7	6	6	1	5
50–54	44	52	31	17	24	5	6	4	2	1
55–59	33	21	14	32	13	3	3	0	2	0
60–64	21	15	10	9	7	3	0	0	0	0
≥65	9	8	11	7	9	0	0	0	1	0
Region of residence^a
Northeast	205	167	136	138	94	16	10	7	7	5
Midwest	142	151	112	77	83	18	10	14	13	7
South	497	451	370	363	266	36	35	29	31	16
West	216	178	157	127	106	22	14	23	15	11
U.S. dependent areas	1	1	0	0	0	0	0	0	0	0
Total	1,060	948	775	706	550	92	69	73	66	38
Total
Age at diagnosis (yr)
13–14	5	10	8	10	5	0	0	0	0	0
15–19	1,358	1,446	1,390	1,365	1,046	56	39	32	33	17
20–24	5,642	5,274	4,970	4,832	3,958	265	217	209	192	135
25–29	6,067	5,923	5,879	5,600	4,655	361	363	405	378	272
30–34	3,847	3,870	3,848	3,902	3,734	281	272	274	315	227
35–39	2,540	2,626	2,510	2,530	2,109	180	204	205	226	170
40–44	1,876	1,686	1,668	1,648	1,505	126	108	108	128	96
45–49	1,694	1,621	1,544	1,366	1,128	100	102	87	96	79
50–54	1,540	1,455	1,260	1,213	1,056	82	87	82	77	54
55–59	885	871	881	917	842	54	49	42	51	33
60–64	448	455	468	469	406	29	25	19	23	19
≥65	342	344	383	352	314	18	18	14	18	8
Region of residence^a
Northeast	3,691	3,559	3,274	3,213	2,624	178	170	188	172	141
Midwest	3,475	3,474	3,261	3,047	2,826	260	201	232	242	171
South	12,966	12,684	12,473	12,364	10,420	636	637	567	650	428
West	5,816	5,629	5,537	5,350	4,702	465	462	478	461	365
U.S. dependent areas	295	234	264	230	185	12	13	12	12	5
Total	26,244	25,580	24,810	24,204	20,758	1,551	1,483	1,477	1,536	1,109

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category; therefore, values may not sum to column total.
Persons whose transmission category is classified as male-to-male sexual contact or male-to-male sexual contact and injection drug use are presented based on sex at birth and include transgender and additional gender identity persons.

^a Data are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 6a. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States
	Male sex at birth					Female sex at birth
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	0	0	0
20–24	3	0	0	2	1	1	1	0	2	0
25–29	5	6	1	1	0	3	2	3	1	6
30–34	0	3	3	2	3	1	1	2	2	3
35–39	1	0	0	4	1	2	3	3	7	4
40–44	2	1	0	3	0	1	2	1	3	3
45–49	2	0	1	1	0	2	2	2	1	1
50–54	0	3	2	1	2	4	2	2	2	1
55–59	3	1	0	0	0	0	0	1	0	0
60–64	0	1	0	0	0	0	0	1	0	0
≥65	0	1	0	0	0	0	1	0	1	1
Region of residence^a
Northeast	0	1	0	0	0	1	1	0	0	0
Midwest	0	2	2	4	3	1	1	2	5	10
South	3	2	1	2	3	1	4	5	7	2
West	14	11	5	8	2	12	9	6	8	8
Total	17	16	9	15	8	15	15	14	19	20
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	1	1	0	0	1	0	0	0	0
25–29	2	1	0	2	1	1	2	0	0	0
30–34	1	0	2	0	2	1	0	2	2	2
35–39	3	2	0	3	1	1	1	1	1	1
40–44	1	3	2	1	2	1	0	0	1	0
45–49	3	2	2	3	3	2	0	0	1	1
50–54	1	1	1	3	2	0	1	0	0	1
55–59	1	1	0	1	1	0	0	0	0	0
60–64	0	0	1	0	2	0	1	0	0	0
≥65	1	0	1	1	1	0	0	0	0	1
Region of residence^a
Northeast	4	4	5	4	3	3	1	1	1	1
Midwest	2	0	1	3	3	0	1	0	0	0
South	2	2	4	3	1	2	2	2	1	2
West	6	5	1	6	8	3	4	2	4	3
Total	14	10	11	15	14	8	7	5	6	6
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	1	0
15–19	4	6	4	4	3	7	8	7	7	7
20–24	20	16	21	22	20	22	30	24	29	20
25–29	29	35	46	51	35	39	38	29	44	34
30–34	33	49	51	57	41	42	40	40	43	36
35–39	44	41	59	45	37	36	39	35	44	30
40–44	44	31	35	44	26	29	40	30	34	18
45–49	41	46	43	31	29	33	41	36	40	25
50–54	57	47	50	40	30	53	40	41	30	24
55–59	43	53	51	39	39	42	31	39	31	31
60–64	36	35	36	42	23	28	25	26	29	16
≥65	29	31	35	33	30	18	19	16	21	10
Region of residence^a
Northeast	103	123	122	117	90	76	92	80	94	50
Midwest	54	61	59	51	42	54	60	46	51	46
South	183	173	204	199	155	182	164	162	164	125
West	39	32	45	40	26	39	35	37	42	29
Total	379	389	430	407	313	350	351	324	351	250
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	1
15–19	2	4	3	1	2	4	4	2	6	2
20–24	18	20	24	17	15	13	19	22	19	8
25–29	37	40	34	44	37	31	18	20	21	18
30–34	48	58	63	44	36	25	29	27	23	26
35–39	43	44	46	48	39	14	24	26	35	23
40–44	23	43	35	38	42	17	21	15	13	16
45–49	34	38	35	25	26	17	16	21	15	9
50–54	39	41	39	27	27	17	14	14	17	11
55–59	25	23	25	25	13	13	7	9	9	9
60–64	12	12	14	13	12	7	7	9	6	9
≥65	13	13	10	12	14	7	4	6	5	3
Region of residence^a
Northeast	97	115	109	85	74	52	47	55	51	38
Midwest	14	16	14	10	13	11	11	9	12	6
South	85	93	95	88	76	54	53	49	55	34
West	98	114	110	111	98	48	52	58	52	56
Total	295	338	329	295	261	165	163	170	170	134
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	1	1	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	0	1	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0
45–49	0	0	1	0	0	0	0	0	0	1
50–54	0	1	0	0	0	2	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	1
≥65	0	0	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	1	1	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	1
West	0	1	1	0	1	2	0	0	0	2
Total	0	1	1	1	3	2	0	0	0	2
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	3	3	4	0	4	5	9	8	6	2
20–24	30	35	36	44	21	44	51	46	44	17
25–29	77	86	99	103	81	93	91	87	89	74
30–34	61	89	107	112	113	70	99	99	106	84
35–39	65	74	113	102	116	59	79	96	97	69
40–44	44	49	63	71	61	45	52	71	75	46
45–49	49	57	51	69	52	45	40	46	55	38
50–54	53	36	50	43	32	38	41	41	38	37
55–59	25	36	35	43	36	20	34	27	35	32
60–64	17	18	22	17	13	16	9	10	12	16
≥65	17	17	10	9	8	10	6	6	5	7
Region of residence^a
Northeast	82	93	115	96	99	87	90	92	78	59
Midwest	80	92	118	105	89	85	92	109	98	63
South	159	196	223	276	243	187	234	224	279	221
West	120	119	134	133	108	85	95	112	108	80
Total	440	501	589	611	539	445	510	537	563	422
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	1	2	3	2	0
20–24	3	2	5	4	5	4	6	9	2	2
25–29	10	8	5	3	4	6	8	12	9	4
30–34	1	6	4	12	10	3	4	6	4	2
35–39	7	5	4	2	10	9	6	6	8	3
40–44	6	4	4	2	2	5	5	5	8	3
45–49	2	5	3	3	3	7	3	5	3	3
50–54	8	3	7	5	3	5	3	5	5	1
55–59	5	2	4	2	2	6	3	1	2	1
60–64	3	1	1	1	2	1	0	3	1	2
≥65	1	2	1	2	0	1	0	1	1	0
Region of residence^a
Northeast	8	10	6	15	7	12	13	10	10	2
Midwest	3	9	8	7	7	6	4	9	11	4
South	16	11	13	10	22	20	15	24	19	11
West	18	8	11	6	5	11	7	12	6	4
Total	44	37	38	37	42	49	39	55	46	21
Total
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	0	1	1
15–19	11	13	13	5	9	17	23	19	21	11
20–24	73	73	87	88	62	86	107	101	96	48
25–29	158	176	186	207	160	174	159	150	164	137
30–34	144	205	230	228	204	143	174	176	179	153
35–39	163	166	223	204	205	122	152	166	192	128
40–44	120	130	140	159	133	98	120	123	133	86
45–49	131	149	134	132	112	104	102	110	115	78
50–54	158	133	149	119	95	120	101	103	93	75
55–59	101	116	116	110	92	81	75	77	78	73
60–64	68	67	74	74	53	52	42	49	48	44
≥65	62	64	57	57	53	36	30	30	34	21
Region of residence^a
Northeast	293	346	358	317	273	230	244	239	234	150
Midwest	153	180	202	182	158	157	169	174	176	128
South	448	477	540	579	501	446	471	465	523	396
West	295	290	307	304	247	201	202	227	221	181
Total	1,189	1,292	1,407	1,381	1,178	1,034	1,086	1,105	1,154	855

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 6b. Diagnoses of HIV infection attributed to injection drug use, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States and 6 dependent areas
	Male sex at birth					Female sex at birth
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	0	0	0
20–24	3	0	0	2	1	1	1	0	2	0
25–29	5	6	1	1	0	3	2	3	1	6
30–34	0	3	3	2	3	1	1	2	2	3
35–39	1	0	0	4	1	2	3	3	7	4
40–44	2	1	0	3	0	1	2	1	3	3
45–49	2	0	1	1	0	2	2	2	1	1
50–54	0	3	2	1	2	4	2	2	2	1
55–59	3	1	0	0	0	0	0	1	0	0
60–64	0	1	0	0	0	0	0	1	0	0
≥65	0	1	0	0	0	0	1	0	1	1
Region of residence^a
Northeast	0	1	0	0	0	1	1	0	0	0
Midwest	0	2	2	4	3	1	1	2	5	10
South	3	2	1	2	3	1	4	5	7	2
West	14	11	5	8	2	12	9	6	8	8
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	17	16	9	15	8	15	15	14	19	20
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	1	1	0	0	1	0	0	0	0
25–29	2	1	0	2	1	1	2	0	0	0
30–34	1	0	2	0	2	1	0	2	2	2
35–39	3	2	0	3	1	1	1	1	1	1
40–44	1	3	2	1	2	1	0	0	1	0
45–49	3	2	2	3	3	2	0	0	1	1
50–54	1	1	1	3	2	0	1	0	0	1
55–59	1	1	0	1	1	0	0	0	0	0
60–64	0	0	1	0	2	0	1	0	0	0
≥65	1	0	1	1	1	0	0	0	0	1
Region of residence^a
Northeast	4	4	5	4	3	3	1	1	1	1
Midwest	2	0	1	3	3	0	1	0	0	0
South	2	2	4	3	1	2	2	2	1	2
West	6	5	1	6	8	3	4	2	4	3
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	14	10	11	16	14	8	7	5	6	6
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	1	0
15–19	4	6	4	4	3	7	8	7	7	7
20–24	20	16	21	22	20	22	30	24	29	20
25–29	29	35	46	51	35	39	38	29	44	34
30–34	33	49	51	57	41	42	40	40	43	36
35–39	44	41	59	45	37	36	39	35	44	30
40–44	44	31	35	44	26	29	40	30	34	18
45–49	41	46	43	31	29	33	41	36	40	25
50–54	57	47	50	40	30	53	40	41	30	24
55–59	43	53	52	40	39	42	31	39	31	31
60–64	36	35	36	42	23	28	25	26	29	16
≥65	29	31	35	33	30	18	19	16	21	10
Region of residence^a
Northeast	103	123	122	117	90	76	92	80	94	50
Midwest	54	61	59	51	42	54	60	46	51	46
South	183	173	204	199	155	182	164	162	164	125
West	39	32	45	40	26	39	35	37	42	29
U.S. dependent areas	1	0	1	1	0	0	0	0	0	0
Total	380	389	431	409	313	350	351	324	351	250
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	1
15–19	2	4	3	1	2	4	4	2	6	2
20–24	20	20	24	17	15	14	19	22	19	8
25–29	38	42	36	45	37	32	18	20	21	18
30–34	49	63	65	44	39	26	29	28	23	26
35–39	48	45	47	53	41	16	26	26	36	23
40–44	27	44	40	42	47	19	21	15	13	17
45–49	39	41	38	27	28	18	19	21	17	9
50–54	42	51	44	29	27	19	15	14	18	12
55–59	32	28	26	26	17	13	8	9	10	9
60–64	16	16	16	16	14	9	8	9	6	9
≥65	16	17	12	17	15	7	4	6	5	3
Region of residence^a
Northeast	97	115	109	85	74	52	47	55	51	38
Midwest	14	16	14	10	13	11	11	9	12	6
South	85	93	95	88	76	54	53	49	55	34
West	98	114	110	111	98	48	52	58	52	56
U.S. dependent areas	35	34	23	23	19	12	9	2	6	2
Total	329	371	352	318	280	177	172	172	175	136
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	0	0	0
20–24	0	0	0	0	0	0	0	0	0	0
25–29	0	0	0	1	1	0	0	0	0	0
30–34	0	0	0	0	0	0	0	0	0	0
35–39	0	0	0	0	1	0	0	0	0	0
40–44	0	0	0	0	0	0	0	0	0	0
45–49	0	0	1	0	0	0	0	0	0	1
50–54	0	1	0	0	0	2	0	0	0	0
55–59	0	0	0	0	0	0	0	0	0	0
60–64	0	0	0	0	0	0	0	0	0	1
≥65	0	0	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	0	0	0	0	0	0	0	0	0	0
Midwest	0	0	0	1	1	0	0	0	0	0
South	0	0	0	0	0	0	0	0	0	1
West	0	1	1	0	1	2	0	0	0	2
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	0	1	2	1	3	2	0	0	0	2
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	3	3	4	0	4	5	9	8	6	2
20–24	30	35	36	44	21	44	51	46	44	17
25–29	77	86	99	103	81	93	91	87	89	74
30–34	61	89	107	112	113	70	99	99	106	84
35–39	65	74	113	102	116	59	79	96	97	69
40–44	44	49	63	71	61	45	52	71	75	46
45–49	49	57	51	69	52	45	40	46	55	38
50–54	53	36	50	43	32	38	41	41	38	37
55–59	25	36	35	43	36	20	34	27	35	32
60–64	17	18	22	17	13	16	9	10	12	16
≥65	17	17	10	9	8	10	6	6	5	7
Region of residence^a
Northeast	82	93	115	96	99	87	90	92	78	59
Midwest	80	92	118	105	89	85	92	109	98	63
South	159	196	223	276	243	187	234	224	279	221
West	120	119	134	133	108	85	95	112	108	80
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	440	501	589	611	539	445	511	537	563	422
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	1	0	0	0	0	1	2	3	2	0
20–24	3	2	5	4	5	4	6	9	2	2
25–29	10	8	5	3	4	6	8	12	9	4
30–34	1	6	4	12	10	3	4	6	4	2
35–39	7	5	4	2	10	9	6	6	8	3
40–44	6	4	4	2	2	5	5	5	8	3
45–49	2	5	3	3	3	7	3	5	3	3
50–54	8	3	7	5	3	5	3	5	5	1
55–59	5	2	4	2	2	6	3	1	2	1
60–64	3	1	1	1	2	1	0	3	1	2
≥65	1	2	1	2	0	1	0	1	1	0
Region of residence^a
Northeast	8	10	6	15	7	12	13	10	10	2
Midwest	3	9	8	7	7	6	4	9	11	4
South	16	11	13	10	22	20	15	24	19	11
West	18	8	11	6	5	11	7	12	6	4
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	44	37	38	37	42	49	39	55	46	21
Total
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	0	1	1
15–19	11	13	13	5	9	17	24	19	21	11
20–24	75	73	87	89	62	87	107	101	96	48
25–29	160	178	188	208	160	175	159	150	164	137
30–34	145	210	232	228	207	144	174	177	179	153
35–39	168	167	224	208	208	124	154	166	193	128
40–44	124	131	145	163	138	100	120	123	133	87
45–49	136	152	137	134	115	105	105	111	117	78
50–54	161	142	154	121	95	122	102	103	94	76
55–59	109	120	118	113	95	81	76	77	79	73
60–64	71	71	76	76	55	54	43	49	48	44
≥65	64	68	59	61	54	36	31	30	34	21
Region of residence^a
Northeast	293	346	358	317	273	230	244	239	234	150
Midwest	153	180	202	182	158	157	169	174	176	128
South	448	477	540	579	501	446	471	465	523	396
West	295	290	307	304	247	201	202	227	221	181
U.S. dependent areas	36	34	24	25	19	12	9	2	6	2
Total	1,225	1,326	1,431	1,406	1,198	1,046	1,095	1,106	1,160	857

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column total.
Persons whose transmission category is classified as injection drug use include transgender and additional gender identity persons.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 7a. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity, and selected characteristics, 2016–2020—United States
	Male sex at birth					Female sex at birth
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	1	1	0
20–24	0	0	1	2	0	0	3	1	2	0
25–29	0	0	1	0	0	4	5	1	2	1
30–34	1	2	1	1	0	3	2	1	3	6
35–39	1	3	1	0	0	6	4	2	6	6
40–44	1	0	0	2	0	6	3	3	6	5
45–49	1	1	0	0	0	3	5	3	3	2
50–54	1	0	0	1	2	1	5	2	2	1
55–59	0	0	1	1	0	2	2	3	1	2
60–64	0	0	0	0	1	2	2	0	1	1
≥65	1	0	0	0	0	1	0	0	1	1
Region of residence^a
Northeast	0	0	1	0	0	1	0	0	0	1
Midwest	1	0	1	2	0	1	3	1	9	4
South	2	3	2	6	2	9	5	8	4	7
West	5	4	3	1	1	15	22	7	12	11
Total	7	7	8	9	3	26	30	15	26	23
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	0	0
15–19	0	0	0	1	1	0	2	0	1	1
20–24	3	2	5	1	1	9	5	6	6	2
25–29	2	4	1	2	3	20	18	15	8	11
30–34	11	4	8	3	2	33	8	16	16	12
35–39	13	10	8	2	3	24	24	11	16	15
40–44	4	3	11	5	2	14	11	12	6	4
45–49	8	6	6	4	4	11	12	8	14	8
50–54	4	3	6	6	4	10	12	9	4	9
55–59	3	3	2	5	4	8	7	9	8	6
60–64	4	4	5	4	2	4	6	6	7	7
≥65	6	3	6	3	5	5	5	7	4	4
Region of residence^a
Northeast	8	9	13	14	3	32	16	27	13	12
Midwest	9	7	2	1	5	13	18	5	11	8
South	24	12	24	12	12	43	30	28	29	24
West	17	15	19	7	10	49	45	38	37	34
Total	58	42	58	35	30	137	109	97	90	79
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	5	3	2	4	2
15–19	39	23	32	26	17	137	140	131	94	79
20–24	161	125	115	119	93	396	404	394	379	277
25–29	248	197	226	178	153	552	516	485	450	377
30–34	230	207	232	189	158	525	535	467	466	398
35–39	234	221	210	181	145	540	476	460	433	326
40–44	224	185	163	162	140	419	409	424	379	286
45–49	221	185	171	196	126	423	398	363	326	277
50–54	229	201	201	175	110	378	344	326	323	223
55–59	182	190	168	154	122	304	296	300	274	200
60–64	121	127	102	131	90	187	198	175	191	139
≥65	122	112	106	123	87	123	167	128	159	91
Region of residence^a
Northeast	349	315	256	244	184	652	638	554	521	403
Midwest	192	190	199	186	137	488	504	484	476	365
South	1,379	1,205	1,196	1,138	867	2,556	2,507	2,343	2,222	1,703
West	93	64	75	66	51	292	236	275	259	203
Total	2,012	1,774	1,725	1,634	1,240	3,988	3,885	3,656	3,478	2,674
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	4	3	0
15–19	4	8	7	7	3	31	39	33	34	30
20–24	50	28	29	27	31	100	118	95	111	96
25–29	72	68	60	76	48	137	139	132	145	99
30–34	89	75	88	67	44	159	134	128	144	98
35–39	88	77	87	69	61	126	125	146	114	104
40–44	83	79	72	72	44	122	100	106	112	87
45–49	77	57	77	54	41	102	120	107	96	71
50–54	56	53	62	55	53	99	83	111	94	72
55–59	38	38	48	38	26	68	70	71	63	55
60–64	29	31	20	33	23	40	40	44	50	37
≥65	24	29	31	21	17	40	37	46	38	25
Region of residence^a
Northeast	161	140	138	108	78	303	261	244	219	196
Midwest	43	28	35	33	17	58	61	56	69	47
South	306	279	321	296	231	437	458	484	470	359
West	101	96	87	83	64	226	227	238	247	172
Total	611	543	581	520	390	1,024	1,007	1,022	1,004	773
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	1
20–24	0	0	0	0	0	1	0	0	1	2
25–29	0	1	0	1	0	0	2	0	2	2
30–34	0	1	1	0	1	1	3	2	1	1
35–39	1	0	0	0	1	1	2	0	2	1
40–44	0	0	0	0	0	0	0	0	1	1
45–49	1	1	0	0	0	0	0	0	0	1
50–54	0	0	0	0	0	1	0	1	1	1
55–59	0	0	0	0	0	0	0	1	0	2
60–64	0	0	0	0	0	0	0	0	0	1
≥65	0	1	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	0	1	0	0	0	0	1	1	0	1
Midwest	1	0	0	0	0	0	0	0	4	0
South	1	1	1	0	0	0	2	1	1	4
West	0	2	0	1	2	4	4	3	4	7
Total	2	4	2	1	2	4	7	5	9	12
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	1	1	0	0
15–19	4	5	4	3	1	30	28	31	31	20
20–24	31	16	20	19	16	103	95	93	91	96
25–29	37	46	48	50	30	132	109	123	130	113
30–34	45	50	61	41	40	140	126	126	125	120
35–39	47	47	51	43	37	108	109	117	121	107
40–44	52	51	42	47	32	94	85	103	97	88
45–49	47	52	54	54	40	102	104	105	103	104
50–54	74	64	44	50	40	101	98	97	95	72
55–59	49	47	50	47	39	92	93	73	82	73
60–64	35	37	38	27	26	53	39	38	46	31
≥65	42	33	32	27	26	20	24	26	23	34
Region of residence^a
Northeast	93	81	81	66	62	121	116	105	112	95
Midwest	48	51	57	59	56	161	150	166	174	147
South	255	237	242	215	163	502	489	497	487	435
West	64	77	63	67	44	190	154	164	172	181
Total	461	446	443	407	325	974	910	933	944	858
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	1	1	0	12	6	13	10	7
20–24	8	4	3	3	3	39	26	19	22	20
25–29	13	11	9	8	0	26	22	35	35	23
30–34	7	14	15	8	4	28	26	34	22	15
35–39	20	10	6	5	2	33	27	23	19	10
40–44	11	12	4	9	5	17	14	14	21	10
45–49	13	9	7	7	2	27	24	26	20	9
50–54	10	6	9	5	2	13	15	10	15	4
55–59	8	7	1	8	2	18	15	9	5	8
60–64	3	6	4	3	1	6	4	10	7	9
≥65	5	5	4	7	2	9	5	8	6	1
Region of residence^a
Northeast	28	23	22	19	4	45	42	42	39	22
Midwest	12	11	6	13	3	45	27	27	31	20
South	52	46	32	27	14	117	89	106	91	65
West	6	7	2	4	3	20	27	26	21	10
Total	99	86	62	64	24	227	184	200	181	116
Total
Age at diagnosis (yr)
13–14	0	0	1	0	0	7	6	7	8	2
15–19	48	37	44	39	22	210	214	210	173	136
20–24	254	175	173	171	143	647	651	608	612	492
25–29	371	327	346	315	234	869	811	790	772	626
30–34	384	352	406	309	249	888	833	774	777	651
35–39	404	369	364	301	249	838	767	759	710	570
40–44	375	330	292	296	223	671	622	662	622	481
45–49	368	311	315	315	212	668	663	611	562	472
50–54	374	327	322	292	209	601	556	555	533	382
55–59	281	285	270	253	193	492	483	466	431	346
60–64	191	206	168	198	142	292	289	273	301	224
≥65	200	183	177	181	136	198	237	214	229	155
Region of residence^a
Northeast	639	568	511	451	331	1,155	1,074	972	903	730
Midwest	306	286	300	294	218	765	763	739	774	591
South	2,019	1,782	1,818	1,696	1,289	3,664	3,580	3,467	3,303	2,596
West	286	265	248	229	175	796	715	751	751	619
Total	3,251	2,902	2,877	2,669	2,012	6,380	6,131	5,928	5,730	4,536

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
Persons whose transmission category is classified as heterosexual contact includes transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 7b. Diagnoses of HIV infection attributed to heterosexual contact, by year of diagnosis, sex assigned at birth, race/ethnicity and selected characteristics, 2016–2020—United States and 6 dependent areas
	Male sex at birth					Female sex at birth
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.	No.	No.	No.	No.	No.
American Indian/Alaska Native
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	1	0	0	0	0	1	1	0
20–24	0	0	1	2	0	0	3	1	2	0
25–29	0	0	1	0	0	4	5	1	2	1
30–34	1	2	1	1	0	3	2	1	3	6
35–39	1	3	1	0	0	6	4	2	6	6
40–44	1	0	0	2	0	6	3	3	6	5
45–49	1	1	0	0	0	3	5	3	3	2
50–54	1	0	0	1	2	1	5	2	2	1
55–59	0	0	1	1	0	2	2	3	1	2
60–64	0	0	0	0	1	2	2	0	1	1
≥65	1	0	0	0	0	1	0	0	1	1
Region of residence^a
Northeast	0	0	1	0	0	1	0	0	0	1
Midwest	1	0	1	2	0	1	3	1	9	4
South	2	3	2	6	2	9	5	8	4	7
West	5	4	3	1	1	15	22	7	12	11
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	7	7	8	9	3	26	30	15	26	23
Asian
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	0	0	0	0
15–19	0	0	0	1	1	0	2	0	1	1
20–24	3	2	5	1	1	9	5	6	6	2
25–29	2	4	1	2	3	20	18	15	8	11
30–34	11	4	8	3	2	33	8	16	16	12
35–39	13	10	8	2	3	24	24	11	16	15
40–44	4	3	11	5	2	14	11	12	6	4
45–49	8	6	6	4	4	11	12	8	14	8
50–54	4	3	6	6	4	10	12	9	4	9
55–59	3	3	2	5	4	8	7	9	8	6
60–64	4	4	5	4	2	4	6	6	7	7
≥65	6	3	6	3	5	5	5	7	4	4
Region of residence^a
Northeast	8	9	13	14	3	32	16	27	13	12
Midwest	9	7	2	1	5	13	18	5	11	8
South	24	12	24	12	12	43	30	28	29	24
West	17	15	19	7	10	49	45	38	37	34
U.S. dependent areas	0	0	0	0	0	0	0	0	0	0
Total	58	42	58	35	30	137	109	97	90	79
Black/African American
Age at diagnosis (yr)
13–14	0	0	0	0	0	5	3	2	4	2
15–19	39	23	32	26	17	137	140	131	94	79
20–24	161	125	115	119	93	396	404	394	379	277
25–29	248	197	227	178	153	552	516	485	450	377
30–34	230	207	232	189	159	525	536	467	466	398
35–39	234	221	210	181	145	540	476	460	433	326
40–44	224	185	163	162	140	419	409	424	379	286
45–49	222	185	172	196	126	423	399	363	326	277
50–54	229	201	201	175	110	378	344	326	323	223
55–59	182	190	169	154	122	304	296	300	274	200
60–64	122	127	102	131	90	187	198	175	191	139
≥65	122	112	106	124	87	123	167	128	159	91
Region of residence^a
Northeast	349	315	256	244	184	652	638	554	521	403
Midwest	192	190	199	186	137	488	504	484	476	365
South	1,379	1,205	1,196	1,138	867	2,556	2,507	2,343	2,222	1,703
West	93	64	75	66	51	292	236	275	259	203
U.S. dependent areas	2	0	3	2	1	0	2	0	1	0
Total	2,014	1,774	1,728	1,636	1,241	3,988	3,887	3,656	3,479	2,674
Hispanic/Latino^b
Age at diagnosis (yr)
13–14	0	0	0	0	0	1	1	4	3	0
15–19	4	9	8	7	3	33	42	35	34	30
20–24	51	36	31	30	33	105	123	104	115	100
25–29	76	72	68	79	52	142	150	139	151	102
30–34	95	83	97	73	45	167	140	133	153	99
35–39	97	88	92	73	65	141	135	151	118	107
40–44	98	89	75	78	47	136	107	114	125	92
45–49	95	61	81	65	43	116	131	121	104	76
50–54	67	59	77	59	57	106	93	122	99	77
55–59	49	47	51	47	34	82	81	79	75	62
60–64	39	41	24	40	30	46	44	49	55	40
≥65	41	40	40	31	20	42	41	52	46	28
Region of residence^a
Northeast	161	140	138	108	78	303	261	244	219	196
Midwest	43	28	35	33	17	58	61	56	69	47
South	306	279	321	296	231	437	458	484	470	359
West	101	96	87	83	64	226	227	238	247	172
U.S. dependent areas	100	83	64	62	38	93	81	80	73	39
Total	711	627	644	581	427	1,117	1,088	1,101	1,077	812
Native Hawaiian/other Pacific Islander
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	0	0	0	0	0	0	1	1	1
20–24	0	1	0	0	0	1	0	0	2	2
25–29	0	1	0	1	0	0	2	0	2	2
30–34	0	1	1	0	1	1	3	2	1	1
35–39	1	0	0	0	1	1	2	0	2	1
40–44	0	0	0	0	0	0	0	0	1	1
45–49	1	1	0	0	0	0	0	0	0	1
50–54	0	0	0	0	0	1	0	1	1	1
55–59	0	0	1	0	0	0	0	1	0	2
60–64	0	0	0	0	0	0	0	0	0	1
≥65	0	1	0	0	0	0	0	0	0	0
Region of residence^a
Northeast	0	1	0	0	0	0	1	1	0	1
Midwest	1	0	0	0	0	0	0	0	4	0
South	1	1	1	0	0	0	2	1	1	4
West	0	2	0	1	2	4	4	3	4	7
U.S. dependent areas	0	1	1	0	0	0	0	0	1	0
Total	3	5	2	1	2	4	7	5	10	12
White
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	1	1	0	0
15–19	4	5	4	3	1	30	28	31	31	20
20–24	31	16	20	19	16	103	95	93	91	96
25–29	37	46	48	50	30	132	109	123	130	113
30–34	45	50	61	41	40	140	126	126	125	120
35–39	47	47	51	43	37	108	109	117	121	107
40–44	52	51	42	47	32	94	85	103	97	88
45–49	47	52	54	55	40	102	104	105	103	104
50–54	74	64	44	50	40	101	99	97	95	72
55–59	49	47	50	47	39	92	93	73	82	73
60–64	35	37	38	27	26	53	39	38	46	31
≥65	42	33	32	27	26	20	24	26	23	34
Region of residence^a
Northeast	93	81	81	66	62	121	116	105	112	95
Midwest	48	51	57	59	56	161	150	166	174	147
South	255	237	242	215	163	502	489	497	487	435
West	64	77	63	67	44	190	154	164	172	181
U.S. dependent areas	0	0	0	1	0	0	2	0	0	0
Total	461	446	443	408	325	974	911	933	944	858
Multiracial
Age at diagnosis (yr)
13–14	0	0	0	0	0	0	0	0	0	0
15–19	0	1	1	1	0	12	6	13	10	7
20–24	8	4	3	3	3	39	26	19	22	20
25–29	13	11	9	8	0	26	22	35	35	23
30–34	7	14	15	8	4	28	26	34	22	15
35–39	20	11	7	5	2	33	27	23	19	10
40–44	11	12	4	9	5	17	14	14	21	10
45–49	13	9	7	7	2	27	24	26	20	9
50–54	10	6	9	5	2	13	15	10	15	4
55–59	8	7	1	8	2	18	15	9	5	8
60–64	3	6	4	3	1	6	4	10	7	9
≥65	5	5	4	7	2	9	5	8	6	1
Region of residence^a
Northeast	28	23	22	19	4	45	42	42	39	22
Midwest	12	11	6	13	3	45	27	27	31	20
South	52	46	32	27	14	117	89	106	91	65
West	6	7	2	4	3	20	27	26	21	10
U.S. dependent areas	0	0	2	0	0	0	0	0	0	0
Total	99	86	64	64	24	227	184	200	181	116
Total
Age at diagnosis (yr)
13–14	0	0	1	0	0	7	6	7	8	2
15–19	48	38	45	39	22	212	218	212	173	136
20–24	255	184	175	174	145	652	656	617	617	496
25–29	375	331	355	318	238	874	822	797	778	629
30–34	390	361	415	315	251	896	840	779	786	652
35–39	413	380	370	305	252	853	777	764	714	573
40–44	390	340	295	303	226	685	629	670	635	486
45–49	387	315	320	327	214	682	675	625	570	477
50–54	385	333	337	296	214	608	567	566	539	387
55–59	292	294	275	262	201	506	494	474	443	353
60–64	203	216	173	205	149	298	293	277	306	227
≥65	217	194	187	192	139	200	241	220	237	158
Region of residence^a
Northeast	639	568	511	451	331	1,155	1,074	972	903	730
Midwest	306	286	300	294	218	765	763	739	774	591
South	2,019	1,782	1,818	1,696	1,289	3,664	3,580	3,467	3,303	2,596
West	286	265	248	229	175	796	715	751	751	619
U.S. dependent areas	102	85	70	65	39	93	85	80	75	39
Total	3,353	2,987	2,947	2,734	2,051	6,473	6,216	6,008	5,805	4,575

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
Persons whose transmission category is classified as heterosexual contact includes transgender and additional gender identity persons.
Includes persons who have ever had sexual contact with a person known to have, or with a risk factor for, HIV infection (e.g., a person who injects drugs).
Excludes men who have ever had sexual contact with both men and women.

^aData are based on residence at time of diagnosis of HIV infection.
^bHispanic/Latino persons can be of any race.

Table 8a. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis and sex assigned at birth, and selected characteristics, 2020 (COVID-19 Pandemic)—United States
	13–14 years		15–17 years		18–19 years		20–22 years		23–24 years		Total
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Sex at birth
Male	6	0.1	240	3.8	851	19.8	2,436	36.9	1,828	41.3	5,361	20.6
Female	6	0.1	49	0.8	108	2.6	289	4.6	269	6.3	721	2.9
Race/Ethnicity
American Indian/Alaska Native	0	0.0	2	1.9	3	4.2	14	12.8	14	19.5	33	7.7
Asian	0	0.0	1	0.2	18	4.0	37	5.2	31	5.9	87	3.1
Black/African American	8	0.7	170	10.1	565	48.4	1,506	82.7	1,038	85.3	3,287	46.6
Hispanic/Latino^b	4	0.2	71	2.3	223	11.1	678	22.8	553	28.6	1,529	12.6
Native Hawaiian/Other Pacific Islander	0	0.0	0	0.0	4	24.3	4	15.7	4	22.9	12	11.8
White	0	0.0	34	0.5	115	2.6	400	5.8	392	8.4	941	3.5
Multiracial	0	0.0	11	2.3	31	10.5	86	20.1	65	24.5	193	10.6
Transmission category^c
Male sex at birth^d
Male-to-male sexual contact	5	—	227	—	811	—	2,268	—	1,653	—	4,964	—
Injection drug use	0	—	1	—	9	—	30	—	31	—	71	—
Male-to-male sexual contact and injection drug use	0	—	4	—	14	—	61	—	73	—	151	—
Heterosexual contact^e	0	—	7	—	15	—	74	—	69	—	165	—
Perinatal^f	1	—	1	—	2	—	2	—	1	—	8	—
Other_g	0	—	0	—	0	—	0	—	1	—	1	—
Subtotal	6	0.1	240	3.8	851	19.8	2,436	36.9	1,828	41.3	5,361	20.6
Female sex at birth^d
Injection drug use	1	—	2	—	8	—	25	—	23	—	59	—
Heterosexual contact^e	2	—	41	—	96	—	253	—	239	—	631	—
Perinatal^f	3	—	6	—	4	—	12	—	6	—	31	—
Other^g	0	—	0	—	0	—	0	—	0	—	0	—
Subtotal	6	0.1	49	0.8	108	2.6	289	4.6	269	6.3	721	2.9
Region of residence^h
Northeast	2	0.2	41	2.0	111	7.7	297	13.8	281	19.9	732	8.8
Midwest	3	0.2	43	1.6	121	6.8	420	15.2	305	17.0	892	8.3
South	5	0.2	163	3.3	590	18.2	1,550	31.2	1,096	33.1	3,404	17.3
West	2	0.1	42	1.4	137	6.9	458	15.0	415	19.3	1,054	8.6
Total	12	0.1	289	2.3	959	11.4	2,725	21.1	2,097	24.2	6,082	11.9

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^bHispanic/Latino persons can be of any race.
^cTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^dData include transgender and additional gender identity persons.
^eSexual contact with a person known to have, or with a risk factor for, HIV infection.
^fIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^hData are based on residence at time of diagnosis of HIV infection.

Table 8b. Diagnoses of HIV infection among persons aged 13–24 years, by age at diagnosis and sex assigned at birth, and selected characteristics, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas
	13–14 years	15–17 years	18–19 years	20–22 years	23–24 years	Total
	No.	No.	No.	No.	No.	No.
Sex at birth
Male	6	242	857	2,448	1,857	5,410
Female	6	49	108	291	271	725
Race/Ethnicity
American Indian/Alaska Native	0	2	3	14	14	33
Asian	0	1	18	37	31	87
Black/African American	8	170	567	1,506	1,038	3,289
Hispanic/Latino^a	4	73	227	692	584	1,580
Native Hawaiian/Other Pacific Islander	0	0	4	4	4	12
White	0	34	115	400	392	941
Multiracial	0	11	31	86	65	193
Transmission category^b
Male sex at birth^c
Male-to-male sexual contact	5	229	817	2,279	1,679	5,009
Injection drug use	0	1	9	30	32	72
Male-to-male sexual contact and injection drug use	0	4	14	62	73	152
Heterosexual contact^d	0	7	15	74	71	167
Perinatal^e	1	1	2	2	1	8
Other^f	0	0	0	0	1	1
Subtotal	6	242	857	2,448	1,857	5,410
Female sex at birth^c
Injection drug use	1	2	8	25	23	59
Heterosexual contact^d	2	41	96	255	241	635
Perinatal^e	3	6	4	12	6	31
Other^f	0	0	0	0	0	0
Subtotal	6	49	108	291	271	725
Region of residence^g
Northeast	2	41	111	297	281	732
Midwest	3	43	121	420	305	892
South	5	163	590	1,550	1,096	3,404
West	2	42	137	458	415	1,054
U.S. dependent areas	0	2	6	14	31	53
Total	12	291	965	2,739	2,128	6,135

Note: Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12 should be interpreted with caution.

^aHispanic/Latino persons can be of any race.
^bTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^cData include transgender and additional gender identity persons.
^dSexual contact with a person known to have, or with a risk factor for, HIV infection.
^eIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^fOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^gData are based on residence at time of diagnosis of HIV infection..

Table 9a. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
Race/ethnicity	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
American Indian/Alaska Native	0	0.0	0	0.0	0	0.0	1	0.2	1	0.2
Asian	8	0.3	7	0.3	6	0.2	6	0.2	2	0.1
Black/African American	76	1.1	56	0.8	50	0.7	32	0.4	32	0.4
Hispanic/Latino^b	18	0.1	16	0.1	11	0.1	7	0.1	9	0.1
Native Hawaiian/other Pacific Islander	0	0.0	1	0.9	0	0.0	0	0.0	1	0.9
White	20	0.1	15	0.1	15	0.1	7	0.0	12	0.0
Multiracial	8	0.3	10	0.4	5	0.2	4	0.2	0	0.0
Total	130	0.2	105	0.2	87	0.2	57	0.1	57	0.1

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population.
^bHispanic/Latino persons can be of any race.

Table 9b. Diagnoses of HIV infection among children aged <13 years, by year of diagnosis and race/ethnicity, 2016–2020—United States and 6 dependent areas
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
Race/ethnicity	No.	No.	No.	No.	No.
American Indian/Alaska Native	0	0	0	1	1
Asian	8	7	6	6	2
Black/African American	76	56	50	32	32
Hispanic/Latino^a	18	16	11	7	9
Native Hawaiian/other Pacific Islander	0	1	0	0	1
White	20	15	15	7	12
Multiracial	8	10	5	4	0
Total	130	105	87	57	57

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^aHispanic/Latino persons can be of any race.

**Table 10a. Diagnoses of HIV infection among Hispanic/Latino persons aged ≥13 years, by transmission category and place of birth, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas**
									Caribbean^a
	United States		South America^b		Central America^c		Mexico		Puerto Rico		Cuba		Other		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.^d	%
Transmission category^e
Male sex at birth^f
Male-to-male sexual contact	2,140	86.8	459	92.2	325	83.2	574	87.0	268	74.6	199	86.5	80.0	73.8	6,359	86.7
Injection drug use	107	4.4	3	0.7	9	2.3	13	2.0	32	8.9	3	1.3	4.0	3.4	280	3.8
Male-to-male sexual contact and injection drug use	112	4.6	7	1.4	9	2.3	15	2.3	9	2.6	1	0.3	2.0	1.6	261	3.6
Heterosexual contact^g	104	4.2	29	5.8	47	12.1	57	8.7	50	13.9	28	12.0	23.0	21.2	427	5.8
Perinatal^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0.0	0.0	0	0.0
Otherⁱ	1	0.0	0	0.0	0	0.1	0	0.1	0	0.0	0	0.0	0.0	0.1	3	0.0
Subtotal	2,465	100	498	100	391	100	660	100	359	100	230	100	109	100	7,331	100
Female sex at birth^f
Injection drug use	63	19.6	1	3.5	3	3.4	4	8.1	8	11.9	0	1.1	3.0	6.0	136	14.3
Heterosexual contact^g	257	80.2	35	95.7	71	96.2	48	88.7	56	88.0	18	97.8	44.0	92.3	812	85.1
Perinatal^h	1	0.2	0	0.5	0	0.4	2	3.0	0	0.2	0	0.6	1.0	1.7	5	0.5
Otherⁱ	0	0.0	0	0.3	0	0.0	0	0.2	0	0.0	0	0.6	0.0	0.0	1	0.1
Subtotal	320	100	37	100	74	100	54	100	64	100	18	100	48	100	954	100
Total	2,785	100	535	100	465	100	714	100	423	100	248	100	157	100	8,285	100

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

^aCountries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).
^bCountries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
^cCountries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
^dTotal includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fData include transgender and additional gender identity persons.
^gSexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
ⁱOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 10b. Diagnoses of HIV infection among transgender and additional gender identity Hispanic/Latino persons ≥13 years, by exposure category and place of birth, 2020 (COVID-19 Pandemic) —United States and 6 dependent areas
									Caribbean^a
	United States		South America^b		Central America^c		Mexico		Puerto Rico		Cuba		Other		Total
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.^d	%
Exposure category^e
Transgender woman^f
Sexual contact^g	64	87.7	7	100	23	95.8	25	89.3	6	85.7	5	100	5	100	179	87.7
Injection drug use	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	0.5
Sexual contact^g and injection drug use	7	9.6	0	0.0	0	0.0	2	7.1	0	0.0	0	0.0	0	0.0	13	6.4
Other^h	2	2.7	0	0.0	1	4.2	1	3.6	1	14.3	0	0.0	0	0.0	11	5.4
Subtotal	73	100	7	100	24	100	28	100	7	100	5	100	5	100	204	100
Transgender man^f
Sexual contact^g	5	55.6	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	6	60.0
Injection drug use	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^g and injection drug use	4	44.4	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	40.0
Other^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Subtotal	9	100	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	10	100
Additional gender identityⁱ						0.0		0.0		0.0		0.0		0.0
Sexual contact^g	3	100	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	3	75.0
Injection drug use	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Sexual contact^g and injection drug use	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
Other^h	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	1	25.0
Subtotal	3	100	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	4	100
Total	85	100	7	100	24	100	28	100	7	100	5	100	5	100	218	100

Note. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and percentages based on these numbers, should be interpreted with caution. Hispanic/Latino persons can be of any race.

^aCountries include Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Cayman Islands, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Montserrat, Puerto Rico, Saint Barthelemy, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Trinidad and Tobago, Turks and Caicos Islands, Virgin Islands (British), and Virgin Islands (U.S).
^bCountries include Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela.
^cCountries include Belize, Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama.
^dTotal includes persons whose place of birth is not among those listed and persons whose place of birth is unknown.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fData include transgender and additional gender identity persons.
^gSexual contact with a person known to have, or with a risk factor for, HIV infection.
^hIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
ⁱOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.

Table 11a. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	12,224	—	12,244	—	12,103	—	12,252	—	13,530	—
Female	4,025	—	3,995	—	3,984	—	3,830	—	4,437	—
Transgender woman/girl^b	120	—	106	—	117	—	144	—	188	—
Transgender man/boy^b	2	—	5	—	5	—	5	—	9	—
Additional gender identity^c	1	—	2	—	1	—	1	—	0	—
Age at death (yr)
<13	1	0.0	2	0.0	1	0.0	2	0.0	4	0.0
13–14	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0
15–19	10	0.0	7	0.0	9	0.0	10	0.0	14	0.1
20–24	155	0.7	144	0.7	121	0.6	122	0.6	131	0.6
25–29	444	1.9	445	1.9	419	1.8	433	1.8	428	1.8
30–34	656	3.0	601	2.7	614	2.8	662	2.9	754	3.3
35–39	838	4.0	864	4.1	813	3.8	855	3.9	889	4.1
40–44	1,130	5.7	970	5.0	958	4.9	932	4.7	1,078	5.3
45–49	1,812	8.7	1,743	8.3	1,599	7.7	1,394	6.8	1,410	7.1
50–54	2,838	13.0	2,726	12.8	2,583	12.4	2,231	10.9	2,225	10.9
55–59	2,985	13.6	2,971	13.5	2,930	13.4	2,909	13.3	3,166	14.7
60–64	2,413	12.4	2,489	12.5	2,526	12.4	2,664	13.0	3,029	14.6
≥65	3,089	6.3	3,390	6.7	3,637	6.9	4,017	7.4	5,036	9.0
Race/ethnicity
American Indian/Alaska Native	47	2.0	47	2.0	48	2.0	58	2.4	78	3.2
Asian^d	100	0.6	88	0.5	84	0.4	101	0.5	97	0.5
Black/African American	7,233	18.0	7,199	17.7	6,984	17.1	6,993	17.0	7,930	19.1
Hispanic/Latino^e	2,632	4.6	2,694	4.6	2,840	4.8	2,741	4.5	3,245	5.3
Native Hawaiian/other Pacific Islander	14	2.5	9	1.5	13	2.2	14	2.3	10	1.6
White	5,310	2.7	5,239	2.6	5,151	2.6	5,234	2.7	5,514	2.8
Multiracial	1,033	15.2	1,074	15.3	1,090	15.2	1,087	14.7	1,290	17.1
Transmission category^f
Male sex at birth (≥13 yrs at death)^g
Male-to-male sexual contact	6,889	—	6,992	—	6,893	—	7,177	—	7,801	—
Injection drug use	2,270	—	2,170	—	2,173	—	2,071	—	2,327	—
Male-to-male sexual contact and injection drug use	1,391	—	1,372	—	1,444	—	1,366	—	1,595	—
Heterosexual contact^h	1,690	—	1,709	—	1,602	—	1,685	—	1,873	—
Perinatalⁱ	40	—	41	—	52	—	42	—	56	—
Other^j	63	—	67	—	57	—	55	—	64	—
Subtotal	12,344	9.3	12,351	9.3	12,220	9.1	12,395	9.2	13,716	10.1
Female sex at birth (≥13 yrs at death)g
Injection drug use	1,390	—	1,381	—	1,323	—	1,304	—	1,425	—
Heterosexual contact^h	2,562	—	2,547	—	2,603	—	2,469	—	2,939	—
Perinatalⁱ	49	—	43	—	36	—	37	—	44	—
Other^j	26	—	28	—	27	—	26	—	37	—
Subtotal	4,027	2.9	3,999	2.9	3,989	2.8	3,835	2.7	4,444	3.1
Child (<13 yrs at death)
Perinatal	1	—	2	—	1	—	1	—	3	—
Other^j	0	—	0	—	0	—	1	—	1	—
Subtotal	1	0.0	2	0.0	1	0.0	2	0.0	4	0.0
Region of residence^k
Northeast	3,709	6.6	3,699	6.6	3,529	6.3	3,632	6.5	4,426	7.9
Midwest	1,858	2.7	1,916	2.8	2,004	2.9	1,939	2.8	2,230	3.3
South	8,049	6.6	7,997	6.5	7,870	6.3	7,894	6.3	8,608	6.8
West	2,756	3.6	2,740	3.5	2,807	3.6	2,767	3.5	2,900	3.7
Total^l	16,372	5.1	16,352	5.0	16,210	5.0	16,232	4.9	18,164	5.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^bTransgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
^lIncludes persons whose race/ethnicity is unknown.

Table 11b. Deaths of persons with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	12,549	—	12,545	—	12,395	—	12,526	—	13,776	—
Female	4,121	—	4,103	—	4,060	—	3,913	—	4,519	—
Transgender woman/girl^b	120	—	108	—	118	—	146	—	189	—
Transgender man/boy^b	2	—	5	—	5	—	5	—	9	—
Additional gender identity^c	1	—	2	—	1	—	1	—	0	—
Age at death (yr)
<13	1	0.0	2	0.0	1	0.0	2	0.0	4	0.0
13–14	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0
15–19	11	0.1	7	0.0	9	0.0	10	0.0	14	0.1
20–24	159	0.7	146	0.7	125	0.6	124	0.6	131	0.6
25–29	451	1.9	451	1.9	427	1.8	439	1.8	430	1.8
30–34	664	3.0	616	2.8	626	2.8	674	3.0	758	3.3
35–39	870	4.1	879	4.1	832	3.8	872	4.0	908	4.1
40–44	1,161	5.8	1,005	5.1	988	5.0	970	4.8	1,107	5.4
45–49	1,864	8.8	1,795	8.5	1,637	7.8	1,431	6.9	1,441	7.1
50–54	2,910	13.2	2,803	13.0	2,634	12.5	2,305	11.1	2,265	11.0
55–59	3,060	13.8	3,053	13.8	3,001	13.5	2,961	13.4	3,235	14.8
60–64	2,468	12.5	2,531	12.6	2,575	12.5	2,716	13.1	3,076	14.6
≥65	3,173	6.4	3,475	6.8	3,724	7.0	4,086	7.5	5,124	9.1
Race/ethnicity
American Indian/Alaska Native	47	—	47	—	48	—	58	—	78	—
Asian^d	100	—	88	—	84	—	101	—	97	—
Black/African American	7,243	—	7,204	—	6,984	—	6,994	—	7,932	—
Hispanic/Latino^e	3,039	—	3,099	—	3,203	—	3,092	—	3,570	—
Native Hawaiian/other Pacific Islander	16	—	9	—	16	—	16	—	10	—
White	5,311	—	5,240	—	5,152	—	5,236	—	5,516	—
Multiracial	1,034	—	1,074	—	1,092	—	1,090	—	1,290	—
Transmission category^f
Male sex at birth (≥13 yrs at death)^g
Male-to-male sexual contact	6,968	—	7,063	—	6,972	—	7,250	—	7,874	—
Injection drug use	2,403	—	2,302	—	2,295	—	2,191	—	2,424	—
Male-to-male sexual contact and injection drug use	1,423	—	1,396	—	1,467	—	1,390	—	1,621	—
Heterosexual contact^h	1,766	—	1,783	—	1,664	—	1,742	—	1,923	—
Perinatalⁱ	46	—	42	—	58	—	44	—	57	—
Other^j	63	—	67	—	58	—	55	—	64	—
Subtotal	12,669	9.5	12,654	9.4	12,513	9.2	12,671	9.3	13,963	10.2
Female sex at birth (≥13 yrs at death)^g
Injection drug use	1,425	—	1,416	—	1,356	—	1,335	—	1,450	—
Heterosexual contact^h	2,620	—	2,619	—	2,644	—	2,519	—	2,995	—
Perinatalⁱ	51	—	44	—	38	—	38	—	44	—
Other^j	27	—	29	—	27	—	27	—	37	—
Subtotal	4,123	2.9	4,107	2.9	4,065	2.9	3,918	2.7	4,526	3.2
Child (<13 yrs at death)
Perinatal	1	—	2	—	1	—	1	—	3	—
Otherj	0	—	0	—	0	—	1	—	1	—
Subtotal	1	0.0	2	0.0	1	0.0	2	0.0	4	0.0
Region of residence^k
Northeast	3,709	6.6	3,699	6.6	3,529	6.3	3,632	6.5	4,426	7.9
Midwest	1,858	2.7	1,916	2.8	2,004	2.9	1,939	2.8	2,230	3.3
South	8,049	6.6	7,997	6.5	7,870	6.3	7,894	6.3	8,608	6.8
West	2,756	3.6	2,740	3.5	2,807	3.6	2,767	3.5	2,900	3.7
U.S. dependent areas	421	11.1	411	11.0	369	10.3	359	10.0	329	9.3
Total^l	16,793	5.1	16,763	5.1	16,579	5.0	16,591	5.0	18,493	5.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^bTransgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
^lIncludes persons whose race/ethnicity is unknown.

Table 12a. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States
	American Indian/Alaska Native		Asian^a		Black/African American		Hispanic/Latino^b		Native Hawaiian/other Pacific Islander		White		Multiracial		Total^c
	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d
Gender
Male	41	—	79	—	5,331	—	2,497	—	8	—	4,672	—	902	—	13,530	—
Female	33	—	15	—	2,502	—	697	—	1	—	820	—	369	—	4,437	—
Transgender woman/girl^e	4	—	3	—	94	—	49	—	1	—	20	—	17	—	188	—
Transgender man/boy^e	0	—	0	—	3	—	2	—	0	—	2	—	2	—	9	—
Additional gender identity^f	0	—	0	—	0	—	0	—	0	—	0	—	0	—	0	—
Age at death (yr)
<13	0	0.0	0	0.0	2	0.0	0	0.0	0	0.0	2	0.0	0	0.0	4	0.0
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	0	0.0	0	0.0	7	0.2	2	0.0	0	0.0	4	0.0	1	0.1	14	0.1
20–24	0	0.0	3	0.2	76	2.5	27	0.6	0	0.0	18	0.2	7	1.0	131	0.6
25–29	2	1.0	5	0.3	210	6.1	92	1.9	0	0.0	89	0.7	30	4.9	428	1.8
30–34	8	4.4	2	0.1	367	11.6	142	3.0	2	3.7	182	1.4	51	10.9	754	3.3
35–39	7	4.4	9	0.6	407	14.6	167	3.7	1	2.0	238	1.9	60	15.6	889	4.1
40–44	4	2.7	8	0.5	515	19.8	216	5.1	2	4.7	257	2.2	76	23.4	1,078	5.3
45–49	9	6.4	7	0.5	642	25.5	280	7.2	0	0.0	365	3.1	107	38.6	1,410	7.1
50–54	11	7.7	14	1.1	886	35.2	443	13.1	2	5.6	717	5.6	152	62.2	2,225	10.9
55–59	11	7.1	12	1.1	1,280	49.3	548	18.7	1	2.9	1,053	7.2	261	111.1	3,166	14.7
60–64	9	6.2	16	1.6	1,370	57.3	486	20.9	1	3.3	927	6.3	220	104.4	3,029	14.6
≥65	17	5.4	21	0.8	2,168	41.8	842	17.2	1	1.6	1,662	3.9	325	71.6	5,036	9.0
Transmission category^g
Male sex at birth (≥13 yrs at death)^h
Male-to-male sexual contact	30	—	60	—	2,516	—	1,404	—	6	—	3,289	—	498	—	7,801	—
Injection drug use	7	—	4	—	1,154	—	525	—	0	—	472	—	164	—	2,327	—
Male-to-male sexual contact and injection drug use	5	—	6	—	448	—	315	—	1	—	660	—	160	—	1,595	—
Heterosexual contactⁱ	3	—	12	—	1,256	—	281	—	2	—	232	—	88	—	1,873	—
Perinatal^j	0	—	0	—	33	—	13	—	0	—	4	—	6	—	56	—
Other^k	0	—	1	—	18	—	9	—	0	—	34	—	3	—	64	—
Subtotal	45	4.6	82	1.1	5,424	33.5	2,546	10.6	9	3.6	4,691	5.6	919	37.6	13,716	10.1
Female sex at birth (≥13 yrs at death)^h
Injection drug use	14	—	3	—	643	—	263	—	0	—	379	—	123	—	1,425	—
Heterosexual contactⁱ	19	—	12	—	1,820	—	423	—	1	—	427	—	238	—	2,939	—
Perinatal^j	0	—	0	—	29	—	8	—	0	—	1	—	6	—	44	—
Other^k	0	—	1	—	13	—	6	—	0	—	14	—	4	—	37	—
Subtotal	33	3.2	15	0.2	2,504	13.8	699	2.9	1	0.4	821	0.9	371	14.4	4,444	3.1
Child (<13 yrs at death)
Perinatal	0	—	0	—	2	—	0	—	0	—	1	—	0	—	3	—
Other^k	0	—	0	—	0	—	0	—	0	—	1	—	0	—	1	—
Subtotal	0	0.0	0	0.0	2	0.0	0	0.0	0	0.0	2	0.0	0	0.0	4	0.0
Region of residence^l
Northeast	0	0.0	21	0.5	1,763	27.8	1,313	15.6	0	0.0	909	2.5	420	41.5	4,426	7.9
Midwest	8	1.9	11	0.5	969	13.4	182	3.2	0	0.0	890	1.7	170	11.8	2,230	3.3
South	27	3.3	17	0.4	4,699	19.4	1,007	4.3	2	2.0	2,351	3.3	505	19.9	8,608	6.8
West	43	4.0	48	0.6	499	13.7	743	3.1	8	1.8	1,364	3.5	195	7.6	2,900	3.7
Total	78	3.2	97	0.5	7,930	19.1	3,245	5.3	10	1.6	5,514	2.8	1,290	17.1	18,164	5.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^bHispanic/Latino persons can be of any race.
^cIncludes persons whose race/ethnicity is unknown.
^dRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^e“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^fAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^gTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^hData include transgender and additional gender identity persons.
ⁱSexual contact with a person known to have, or with a risk factor for, HIV infection.
^jIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^kOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^lData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 12b. Deaths of persons with diagnosed HIV infection, by race/ethnicity and selected characteristics, 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
	American Indian/Alaska Native	Asian^a	Black/African American	Hispanic/Latino^b	Native Hawaiian/other Pacific Islander	White	Multiracial	Total^c
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	41	79	5,332	2,740	8	4,674	902	13,776
Female	33	15	2,503	778	1	820	369	4,519
Transgender woman/girl^d	4	3	94	50	1	20	17	189
Transgender man/boy^d	0	0	3	2	0	2	2	9
Additional gender identity^e	0	0	0	0	0	0	0	0
Age at death (yr)
<13	0	0	2	0	0	2	0	4
13–14	0	0	0	0	0	0	0	0
15–19	0	0	7	2	0	4	1	14
20–24	0	3	76	27	0	18	7	131
25–29	2	5	210	94	0	89	30	430
30–34	8	2	367	146	2	182	51	758
35–39	7	9	407	186	1	238	60	908
40–44	4	8	515	245	2	257	76	1,107
45–49	9	7	642	311	0	365	107	1,441
50–54	11	14	886	482	2	718	152	2,265
55–59	11	12	1,281	616	1	1,053	261	3,235
60–64	9	16	1,370	533	1	927	220	3,076
≥65	17	21	2,169	928	1	1,663	325	5,124
Transmission category^f
Male sex at birth (≥13 yrs at death)^g
Male-to-male sexual contact	30	60	2,516	1,475	6	3,290	498	7,874
Injection drug use	7	4	1,154	622	0	472	164	2,424
Male-to-male sexual contact and injection drug use	5	6	448	341	1	661	160	1,621
Heterosexual contact^h	3	12	1,257	329	2	232	88	1,922
Perinatalⁱ	0	0	33	14	0	4	6	57
Other^j	0	1	18	9	0	34	3	64
Subtotal	45	82	5,425	2,790	9	4,693	919	13,963
Female sex at birth (≥13 yrs at death)^g
Injection drug use	14	3	643	288	0	379	123	1,450
Heterosexual contact^h	19	12	1,821	478	1	427	238	2,995
Perinatalⁱ	0	0	29	8	0	1	6	44
Other^j	0	1	13	6	0	14	4	37
Subtotal	33	15	2,505	780	1	821	371	4,526
Child (<13 yrs at death)
Perinatal	0	0	2	0	0	1	0	3
Other^j	0	0	0	0	0	1	0	1
Subtotal	0	0	2	0	0	2	0	4
Region of residence^k
Northeast	0	21	1,763	1,313	0	909	420	4,426
Midwest	8	11	969	182	0	890	170	2,230
South	27	17	4,699	1,007	2	2,351	505	8,608
West	43	48	499	743	8	1,364	195	2,900
U.S. dependent areas	0	0	2	325	0	2	0	329
Total	78	97	7,932	3,570	10	5,516	1,290	18,493

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, should be interpreted with caution.

^aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^bHispanic/Latino persons can be of any race.
^cIncludes persons whose race/ethnicity is unknown.
^d“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^eAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 13a. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at death (yr)
13–14	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0
15–19	5	0.0	5	0.0	5	0.0	8	0.1	10	0.1
20–24	111	1.0	112	1.0	95	0.9	94	0.8	101	0.9
25–29	350	3.0	347	2.9	346	2.9	368	3.1	334	2.8
30–34	474	4.3	446	4.0	464	4.1	510	4.5	571	4.9
35–39	584	5.6	625	5.9	576	5.3	617	5.7	654	6.0
40–44	743	7.6	659	6.8	631	6.5	642	6.5	762	7.5
45–49	1,303	12.6	1,226	11.8	1,127	11.0	976	9.7	971	9.8
50–54	2,125	19.8	2,035	19.4	1,904	18.6	1,651	16.4	1,651	16.4
55–59	2,327	21.8	2,249	21.1	2,255	21.2	2,266	21.3	2,444	23.2
60–64	1,844	19.8	1,933	20.3	1,909	19.6	2,056	20.9	2,322	23.3
≥65	2,477	11.4	2,714	12.1	2,908	12.5	3,206	13.3	3,896	15.7
Race/ethnicity
American Indian/Alaska Native	38	4.0	33	3.4	33	3.4	39	4.0	45	4.6
Asian^c	87	1.2	73	1.0	73	1.0	93	1.2	82	1.1
Black/African American	4,855	31.2	4,909	31.2	4,708	29.6	4,791	29.9	5,424	33.5
Hispanic/Latino^d	2,033	9.2	2,109	9.3	2,257	9.7	2,174	9.2	2,546	10.6
Native Hawaiian/other Pacific Islander	10	4.3	5	2.1	12	5.0	9	3.6	9	3.6
White	4,552	5.4	4,413	5.2	4,320	5.1	4,464	5.3	4,691	5.6
Multiracial	766	36.0	808	36.7	817	35.8	822	34.8	919	37.6
Transmission category^e
Male-to-male sexual contact	6,889	—	6,992	—	6,893	—	7,177	—	7,801	—
Injection drug use	2,270	—	2,170	—	2,173	—	2,071	—	2,327	—
Male-to-male sexual contact and injection drug use	1,391	—	1,372	—	1,444	—	1,366	—	1,595	—
Heterosexual contact^f	1,690	—	1,709	—	1,602	—	1,685	—	1,873	—
Perinatal^g	40	—	41	—	52	—	42	—	56	—
Other^h	63	—	67	—	57	—	55	—	64	—
Region of residenceⁱ
Northeast	2,628	11.4	2,623	11.4	2,490	10.8	2,586	11.2	3,151	13.6
Midwest	1,475	5.3	1,513	5.4	1,598	5.7	1,554	5.5	1,795	6.4
South	5,838	11.8	5,820	11.6	5,707	11.3	5,861	11.5	6,252	12.1
West	2,403	7.6	2,395	7.5	2,425	7.5	2,394	7.4	2,518	7.7
Subtotal	12,344	9.3	12,351	9.3	12,220	9.1	12,395	9.2	13,716	10.1
Female sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	5	0.0	2	0.0	4	0.0	2	0.0	4	0.0
20–24	44	0.4	32	0.3	26	0.2	28	0.3	30	0.3
25–29	94	0.8	98	0.9	73	0.6	65	0.6	94	0.8
30–34	182	1.7	155	1.4	150	1.4	152	1.4	183	1.6
35–39	254	2.4	239	2.3	237	2.2	238	2.2	235	2.2
40–44	387	3.9	311	3.2	327	3.3	290	2.9	316	3.1
45–49	509	4.8	517	4.9	472	4.5	418	4.1	439	4.3
50–54	713	6.4	691	6.4	679	6.4	580	5.6	574	5.5
55–59	658	5.8	722	6.4	675	6.0	643	5.7	722	6.5
60–64	569	5.6	556	5.3	617	5.8	608	5.7	707	6.5
≥65	612	2.2	676	2.4	729	2.5	811	2.7	1,140	3.7
Race/ethnicity
American Indian/Alaska Native	9	0.9	14	1.4	15	1.5	19	1.9	33	3.2
Asian^c	13	0.2	15	0.2	11	0.1	8	0.1	15	0.2
Black/African American	2,377	13.6	2,289	13.0	2,275	12.8	2,201	12.3	2,504	13.8
Hispanic/Latino^d	599	2.7	585	2.6	583	2.6	566	2.4	699	2.9
Native Hawaiian/other Pacific Islander	4	1.7	4	1.7	1	0.4	5	2.0	1	0.4
White	758	0.9	825	0.9	831	1.0	770	0.9	821	0.9
Multiracial	267	11.8	266	11.3	273	11.3	265	10.6	371	14.4
Transmission category^e
Injection drug use	1,390	—	1,381	—	1,323	—	1,304	—	1,425	—
Heterosexual contact^f	2,562	—	2,547	—	2,603	—	2,469	—	2,939	—
Perinatal^g	49	—	43	—	36	—	37	—	44	—
Other^h	26	—	28	—	27	—	26	—	37	—
Region of residenceⁱ
Northeast	1,081	4.4	1,076	4.4	1,038	4.2	1,046	4.2	1,273	5.2
Midwest	382	1.3	402	1.4	406	1.4	384	1.3	435	1.5
South	2,211	4.2	2,176	4.1	2,163	4.0	2,032	3.8	2,355	4.3
West	353	1.1	345	1.1	382	1.2	373	1.1	381	1.1
Subtotal	4,027	2.9	3,999	2.9	3,989	2.8	3,835	2.7	4,444	3.1
Total	16,371	6.1	16,350	6.0	16,209	5.9	16,230	5.9	18,160	6.5

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^bData include transgender and additional gender identity persons.
^cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fSexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 13b. Deaths of persons aged ≥13 years with diagnosed HIV infection, by year of death, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at death (yr)
13–14	1	0.0	0	0.0	0	0.0	1	0.0	0	0.0
15–19	6	0.1	5	0.0	5	0.0	8	0.1	10	0.1
20–24	114	1.0	113	1.0	99	0.9	96	0.9	101	0.9
25–29	356	3.0	351	2.9	353	2.9	372	3.1	336	2.8
30–34	479	4.3	456	4.1	472	4.2	516	4.5	573	4.9
35–39	609	5.8	636	5.9	589	5.4	628	5.7	669	6.1
40–44	763	7.7	687	7.0	655	6.6	669	6.7	786	7.7
45–49	1,346	12.9	1,267	12.1	1,154	11.1	1,003	9.8	989	9.9
50–54	2,181	20.1	2,094	19.7	1,942	18.7	1,711	16.8	1,681	16.5
55–59	2,384	22.1	2,307	21.4	2,311	21.5	2,306	21.4	2,495	23.5
60–64	1,889	20.1	1,962	20.4	1,951	19.9	2,097	21.1	2,356	23.4
≥65	2,541	11.5	2,776	12.2	2,982	12.6	3,264	13.4	3,967	15.8
Race/ethnicity
American Indian/Alaska Native	38	—	33	—	33	—	39	—	45	—
Asian^c	87	—	73	—	73	—	93	—	82	—
Black/African American	4,862	—	4,913	—	4,708	—	4,792	—	5,425	—
Hispanic/Latino^d	2,349	—	2,407	—	2,546	—	2,443	—	2,790	—
Native Hawaiian/other Pacific Islander	11	—	5	—	13	—	11	—	9	—
White	4,552	—	4,414	—	4,321	—	4,466	—	4,693	—
Multiracial	767	—	808	—	819	—	824	—	919	—
Transmission category^e
Male-to-male sexual contact	6,968	—	7,063	—	6,972	—	7,249	—	7,874	—
Injection drug use	2,403	—	2,302	—	2,295	—	2,191	—	2,424	—
Male-to-male sexual contact and injection drug use	1,423	—	1,396	—	1,467	—	1,390	—	1,621	—
Heterosexual contact^f	1,766	—	1,783	—	1,664	—	1,742	—	1,923	—
Perinatal^g	46	—	42	—	58	—	44	—	57	—
Other^h	63	—	67	—	58	—	55	—	64	—
Region of residenceⁱ
Northeast	2,628	11.4	2,623	11.4	2,490	10.8	2,586	11.2	3,151	13.6
Midwest	1,475	5.3	1,513	5.4	1,598	5.7	1,554	5.5	1,795	6.4
South	5,838	11.8	5,820	11.6	5,707	11.3	5,861	11.5	6,252	12.1
West	2,403	7.6	2,395	7.5	2,425	7.5	2,394	7.4	2,518	7.7
US dependent areas	325	21.2	303	20.0	293	19.9	276	18.7	247	16.8
Subtotal	12,669	9.5	12,654	9.4	12,513	9.2	12,671	9.3	13,963	10.2
Female sex at birth^b
Age at death (yr)
13–14	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
15–19	5	0.0	2	0.0	4	0.0	2	0.0	4	0.0
20–24	45	0.4	33	0.3	26	0.2	28	0.3	30	0.3
25–29	95	0.8	100	0.9	74	0.6	67	0.6	94	0.8
30–34	185	1.7	160	1.5	154	1.4	158	1.4	185	1.6
35–39	261	2.5	243	2.3	243	2.2	244	2.2	239	2.2
40–44	398	4.0	318	3.2	333	3.3	301	3.0	321	3.1
45–49	518	4.9	528	4.9	483	4.6	428	4.1	452	4.4
50–54	729	6.5	709	6.5	692	6.5	594	5.6	584	5.6
55–59	676	5.9	746	6.5	690	6.1	655	5.8	740	6.6
60–64	579	5.6	569	5.4	624	5.8	619	5.7	720	6.6
≥65	632	2.3	699	2.4	742	2.5	822	2.7	1,157	3.7
Race/ethnicity
American Indian/Alaska Native	9	—	14	—	15	—	19	—	33	—
Asian^c	13	—	15	—	11	—	8	—	15	—
Black/African American	2,380	—	2,290	—	2,275	—	2,201	—	2,505	—
Hispanic/Latino^d	690	—	692	—	657	—	648	—	780	—
Native Hawaiian/other Pacific Islander	5	—	4	—	3	—	5	—	1	—
White	759	—	825	—	831	—	770	—	821	—
Multiracial	267	—	266	—	273	—	266	—	371	—
Transmission category^e
Injection drug use	1,425	—	1,416	—	1,356	—	1,335	—	1,450	—
Heterosexual contact^f	2,620	—	2,619	—	2,644	—	2,519	—	2,995	—
Perinatal^g	51	—	44	—	38	—	38	—	44	—
Other^h	27	—	29	—	27	—	27	—	37	—
Region of residenceⁱ
Northeast	1,081	4.4	1,076	4.4	1,038	4.2	1,046	4.2	1,273	5.2
Midwest	382	1.3	402	1.4	406	1.4	384	1.3	435	1.5
South	2,211	4.2	2,176	4.1	2,163	4.0	2,032	3.8	2,355	4.3
West	353	1.1	345	1.1	382	1.2	373	1.1	381	1.1
US dependent areas	96	5.6	108	6.4	76	4.6	83	5.0	82	5.0
Subtotal	4,123	2.9	4,107	2.9	4,065	2.9	3,918	2.7	4,526	3.2
Total	16,792	6.1	16,761	6.1	16,578	6.0	16,589	5.9	18,489	6.6

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^bData include transgender and additional gender identity persons.
^cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fSexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 14a. Deaths of transgender and additional gender identity persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	1	2	1	5	7
25–29	10	8	12	17	15
30–34	10	9	9	19	26
35–39	13	15	13	16	26
40–44	12	13	12	17	21
45–49	21	18	12	17	25
50–54	13	10	19	17	19
55–59	17	18	17	17	24
60–64	11	7	11	12	12
≥65	12	6	11	7	13
Race/ethnicity
American Indian/Alaska Native	0	0	2	1	4
Asian^b	3	0	2	1	3
Black/African American	55	43	45	69	94
Hispanic/Latino^c	27	36	34	33	49
Native Hawaiian/other Pacific Islander	1	1	0	0	1
White	22	18	21	23	20
Multiracial	12	8	13	17	17
Exposure category^d
Sexual contact^e	83	77	77	98	128
Injection drug use	0	0	0	1	2
Sexual contact^e and injection drug use	33	26	38	39	53
Other^f	4	3	2	6	5
Region of residence^g
Northeast	27	25	32	39	58
Midwest	12	11	11	22	22
South	41	39	42	54	63
West	40	31	32	29	45
Subtotal	120	106	117	144	188
Transgender man^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	1
25–29	0	0	0	1	0
30–34	0	1	0	0	1
35–39	2	0	0	0	1
40–44	0	0	0	0	2
45–49	0	1	2	0	1
50–54	0	0	1	1	0
55–59	0	2	1	1	1
60–64	0	0	0	2	1
≥65	0	1	1	0	1
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	3	0	1	3
Hispanic/Latino^c	0	1	2	2	2
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	1	0	2	1	2
Multiracial	0	1	1	1	2
Exposure category^d
Sexual contact^e	2	3	0	3	6
Injection drug use	0	0	0	0	0
Sexual contact^e and injection drug use	0	2	5	1	3
Other^f	0	0	0	1	0
Region of residence^g
Northeast	0	1	0	1	2
Midwest	0	0	1	1	2
South	2	3	3	3	3
West	0	1	1	0	2
Subtotal	2	5	5	5	9
Additional gender identity^h
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	0
25–29	0	0	0	0	0
30–34	1	1	0	0	0
35–39	0	0	0	0	0
40–44	0	0	0	1	0
45–49	0	0	0	0	0
50–54	0	0	0	0	0
55–59	0	1	1	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	0	0	1	0
Hispanic/Latino^c	0	1	1	0	0
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	0	1	0	0	0
Multiracial	0	0	0	0	0
Exposure category^d
Sexual contact^e	1	1	0	1	0
Injection drug use	0	0	0	0	0
Sexual contact^e and injection drug use	0	1	1	0	0
Other^f	0	0	0	0	0
Region of residence^g
Northeast	0	1	0	1	0
Midwest	0	1	0	0	0
South	0	0	0	0	0
West	1	0	1	0	0
Subtotal	1	2	1	1	0
Total	123	113	123	150	197

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Additional gender identity not included due to small numbers.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^cHispanic/Latino persons can be of any race.
^dClassification of adults and adolescents based on their risk factors that may have been responsible for HIV transmission; classification has no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically adjusted to account for missing exposure category.
^eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^fOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^gData are based on residence at the time of death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
^hAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 14b. Deaths of transgender and additional gender identity persons aged ≥13 years with diagnosed HIV infection, by year of death and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	1	2	1	5	7
25–29	10	8	12	17	15
30–34	10	9	9	19	26
35–39	13	16	13	16	26
40–44	12	13	12	17	21
45–49	21	18	12	18	25
50–54	13	11	19	17	20
55–59	17	18	17	17	24
60–64	11	7	11	12	12
≥65	12	6	12	8	13
Race/ethnicity
American Indian/Alaska Native	0	0	2	1	4
Asian^b	3	0	2	1	3
Black/African American	55	43	45	69	94
Hispanic/Latino^c	27	38	35	35	50
Native Hawaiian/other Pacific Islander	1	1	0	0	1
White	22	18	21	23	20
Multiracial	12	8	13	17	17
Exposure category^d
Sexual contact^e	83	77	78	98	129
Injection drug use	0	0	0	1	2
Sexual contact^e and injection drug use	33	28	38	41	53
Other^f	4	3	2	6	5
Region of residence^g
Northeast	27	25	32	39	58
Midwest	12	11	11	22	22
South	41	39	42	54	63
West	40	31	32	29	45
US dependent areas	0	2	1	2	1
Subtotal	120	108	118	146	189
Transgender man^a
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	1
25–29	0	0	0	1	0
30–34	0	1	0	0	1
35–39	2	0	0	0	1
40–44	0	0	0	0	2
45–49	0	1	2	0	1
50–54	0	0	1	1	0
55–59	0	2	1	1	1
60–64	0	0	0	2	1
≥65	0	1	1	0	1
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	3	0	1	3
Hispanic/Latino^c	0	1	2	2	2
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	1	0	2	1	2
Multiracial	0	1	1	1	2
Exposure category^d
Sexual contact^e	2	3	0	3	6
Injection drug use	0	0	0	0	0
Sexual contact^e and injection drug use	0	2	5	1	3
Other^f	0	0	0	1	0
Region of residence^g
Northeast	0	1	0	1	2
Midwest	0	0	1	1	2
South	2	3	3	3	3
West	0	1	1	0	2
US dependent areas	0	0	0	0	0
Subtotal	2	5	5	5	9
Additional gender identity^h
Age at death (yr)
13–14	0	0	0	0	0
15–19	0	0	0	0	0
20–24	0	0	0	0	0
25–29	0	0	0	0	0
30–34	1	1	0	0	0
35–39	0	0	0	0	0
40–44	0	0	0	1	0
45–49	0	0	0	0	0
50–54	0	0	0	0	0
55–59	0	1	1	0	0
60–64	0	0	0	0	0
≥65	0	0	0	0	0
Race/ethnicity
American Indian/Alaska Native	0	0	0	0	0
Asian^b	0	0	0	0	0
Black/African American	1	0	0	1	0
Hispanic/Latino^c	0	1	1	0	0
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	0	1	0	0	0
Multiracial	0	0	0	0	0
Exposure category^d
Sexual contact^e	1	1	0	1	0
Injection drug use	0	0	0	0	0
Sexual contact^e and injection drug use	0	1	1	0	0
Other^f	0	0	0	0	0
Region of residence^g
Northeast	0	1	0	1	0
Midwest	0	1	0	0	0
South	0	0	0	0	0
West	1	0	1	0	0
US dependent areas	0	0	0	0	0
Subtotal	1	2	1	1	0
Total	123	115	124	152	198

Note. Deaths of persons with a diagnosis of HIV infection may be due to any cause. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.
Additional gender identity not included due to small numbers.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^cHispanic/Latino persons can be of any race.
^dClassification of adults and adolescents based on their risk factors that may have been responsible for HIV transmission; classification has no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. The categories are mutually exclusive. Data were not statistically adjusted to account for missing exposure category.
^eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^fOther risk factors including perinatal, hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^gData are based on residence at the time of death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.
^hAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 15a. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	731,528	—	750,778	—	769,364	—	787,151	—	798,697	—
Female	231,679	—	235,624	—	239,274	—	242,869	—	244,205	—
Transgender woman/girl^b	9,855	—	10,378	—	10,918	—	11,466	—	11,949	—
Transgender man/boy^b	362	—	390	—	437	—	479	—	509	—
Additional gender identity^c	166	—	184	—	202	—	226	—	243	—
Age at end of year
<13	2,210	4.2	2,057	3.9	1,894	3.6	1,669	3.2	1,444	2.8
13–14	679	8.3	669	8.1	666	8.0	650	7.8	640	7.6
15–19	4,639	21.9	4,536	21.5	4,358	20.7	4,238	20.1	3,778	18.0
20–24	29,783	133.2	28,381	128.6	26,949	123.5	25,982	120.0	24,186	112.0
25–29	68,250	297.5	70,339	301.1	70,809	300.7	69,281	294.3	65,455	281.8
30–34	78,999	361.8	82,684	376.5	87,608	395.8	93,030	414.1	97,029	424.9
35–39	89,346	429.9	91,617	432.3	93,487	433.8	95,411	438.6	96,659	442.8
40–44	97,070	493.3	95,806	489.4	96,455	490.0	97,980	491.9	100,348	494.1
45–49	135,715	649.1	129,676	620.5	123,026	593.9	116,855	573.1	109,234	547.0
50–54	165,941	761.3	162,434	761.5	157,168	753.6	150,353	734.5	145,107	711.5
55–59	135,369	617.0	143,953	656.0	152,372	695.3	159,672	730.1	162,542	752.4
60–64	87,269	448.7	95,802	480.7	103,919	511.8	111,790	543.7	120,013	577.0
≥65	78,320	159.2	89,400	176.1	101,484	193.8	115,280	213.3	129,168	232.1
Race/ethnicity
American Indian/Alaska Native	2,690	112.9	2,848	118.8	2,976	123.5	3,124	129.0	3,248	133.5
Asian^d	12,948	72.5	13,908	75.8	14,795	79.0	15,558	81.6	16,198	83.6
Black/African American	396,530	985.3	406,215	1000.8	415,577	1016.1	424,689	1,031.0	430,015	1,038.0
Hispanic/Latino^e	217,205	379.2	225,188	385.6	233,010	391.8	240,872	398.8	246,097	401.4
Native Hawaiian/other Pacific Islander	738	129.5	777	133.4	827	139.3	880	145.7	936	152.6
White	290,404	146.7	294,999	149.1	299,442	151.6	303,443	153.8	305,956	155.5
Multiracial	52,339	768.6	52,685	752.2	52,834	734.6	52,895	717.1	52,423	693.7
Transmission category^f
Male sex at birth (≥13 yrs at end of year)^g
Male-to-male sexual contact	531,004	—	550,084	—	568,405	—	586,044	—	599,433	—
Injection drug use	68,935	—	68,166	—	67,525	—	66,954	—	65,912	—
Male-to-male sexual contact and injection drug use	56,977	—	57,124	—	57,180	—	57,361	—	56,882	—
Heterosexual contact^h	76,039	—	77,339	—	78,725	—	79,821	—	80,035	—
Perinatalⁱ	4,732	—	4,832	—	4,928	—	5,051	—	5,135	—
Other^j	2,799	—	2,800	—	2,791	—	2,794	—	2,783	—
Subtotal	740,486	560.5	760,344	570.9	779,554	581.3	798,026	591.2	810,180	596.8
Female sex at birth (≥13 yrs at end of year)^g
Injection drug use	49,201	—	48,995	—	48,837	—	48,727	—	48,195	—
Heterosexual contact^h	174,674	—	178,746	—	182,501	—	186,172	—	188,033	—
Perinatalⁱ	5,351	—	5,532	—	5,713	—	5,876	—	6,015	—
Other^j	1,668	—	1,680	—	1,697	—	1,722	—	1,736	—
Subtotal	230,894	167.1	234,953	168.8	238,747	170.3	242,496	171.9	243,979	172.0
Child (<13 yrs at end of year)
Perinatal	1,827	—	1,701	—	1,548	—	1,372	—	1,194	—
Other^j	383	—	356	—	346	—	297	—	250	—
Subtotal	2,210	4.2	2,057	3.9	1,894	3.6	1,669	3.2	1,444	2.8
Region of residence^k
Northeast	230,044	410.3	232,022	413.7	234,097	417.4	235,593	420.7	235,337	421.4
Midwest	115,828	170.3	118,984	174.6	122,094	178.9	124,872	182.7	126,929	185.8
South	436,538	356.6	449,534	363.7	461,779	370.5	474,316	377.4	482,479	380.9
West	191,180	249.7	196,814	254.7	202,225	259.8	207,410	264.9	210,858	268.1
Total^l	973,590	301.4	997,354	306.8	1,020,195	312.1	1,042,191	317.4	1,055,603	320.4

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on address of residence at the end of the specified year (i.e., most recent known address).
^lIncludes persons whose race/ethnicity is unknown.

Table 15b. Persons living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Gender
Male	743,223	—	762,324	—	780,831	—	798,709	—	810,267	—
Female	236,769	—	240,574	—	244,164	—	247,754	—	249,044	—
Transgender woman/girl^b	9,890	—	10,413	—	10,949	—	11,499	—	11,985	—
Transgender man/boy^b	363	—	391	—	439	—	481	—	512	—
Additional gender identity^c	167	—	184	—	203	—	226	—	243	—
Age at end of year
<13	2,224	4.2	2,066	3.9	1,900	3.6	1,674	3.2	1,447	2.8
13–14	682	8.2	675	8.1	674	8.0	654	7.8	643	7.6
15–19	4,686	21.9	4,581	21.4	4,400	20.6	4,264	20.0	3,800	17.9
20–24	30,131	133.1	28,677	128.5	27,216	123.3	26,232	119.8	24,403	111.8
25–29	69,013	297.6	71,045	300.9	71,504	300.6	69,966	294.1	66,068	281.4
30–34	79,964	362.5	83,595	377.0	88,485	396.2	93,936	414.3	97,943	424.8
35–39	90,749	431.7	92,903	433.7	94,664	434.9	96,491	439.3	97,688	443.4
40–44	98,741	495.8	97,393	491.7	97,974	492.2	99,438	493.7	101,775	495.8
45–49	138,131	653.0	131,864	623.8	125,006	596.7	118,722	575.7	110,929	549.3
50–54	168,965	766.2	165,360	766.2	159,981	758.2	152,961	738.6	147,624	715.6
55–59	137,939	621.7	146,606	660.7	155,114	700.0	162,572	735.1	165,411	757.1
60–64	89,003	452.3	97,654	484.4	105,941	516.0	113,927	548.0	122,308	581.5
≥65	80,184	160.7	91,467	177.8	103,727	195.5	117,832	215.2	132,012	234.1
Race/ethnicity
American Indian/Alaska Native	2,692	—	2,850	—	2,978	—	3,126	—	3,250	—
Asian^d	13,000	—	13,964	—	14,856	—	15,626	—	16,266	—
Black/African American	396,835	—	406,513	—	415,886	—	425,003	—	430,332	—
Hispanic/Latino^e	233,531	—	241,218	—	248,889	—	256,817	—	262,007	—
Native Hawaiian/other Pacific Islander	767	—	809	—	858	—	912	—	968	—
White	290,485	—	295,085	—	299,526	—	303,536	—	306,048	—
Multiracial	52,363	—	52,710	—	52,856	—	52,916	—	52,447	—
Transmission category^f
Male sex at birth (≥13 yrs at end of year)^g
Male-to-male sexual contact	535,741	—	554,845	—	573,263	—	591,073	—	604,590	—
Injection drug use	72,548	—	71,657	—	70,889	—	70,228	—	69,099	—
Male-to-male sexual contact and injection drug use	57,809	—	57,919	—	57,945	—	58,120	—	57,629	—
Heterosexual contact^h	78,423	—	79,709	—	81,079	—	82,192	—	82,394	—
Perinatalⁱ	4,864	—	4,963	—	5,058	—	5,183	—	5,265	—
Other^j	2,826	—	2,827	—	2,817	—	2,820	—	2,808	—
Subtotal	752,210	562.9	771,920	573.1	791,050	583.5	809,615	593.3	821,785	598.9
Female sex at birth (≥13 yrs at end of year)^g
Injection drug use	50,248	—	49,985	—	49,792	—	49,670	—	49,114	—
Heterosexual contact^h	178,573	—	182,568	—	186,307	—	189,994	—	191,832	—
Perinatalⁱ	5,477	—	5,655	—	5,829	—	5,984	—	6,126	—
Other^j	1,680	—	1,692	—	1,708	—	1,732	—	1,747	—
Subtotal	235,978	168.7	239,900	170.3	243,636	171.8	247,380	173.3	248,819	173.4
Child (<13 yrs at end of year)
Perinatal	1,841	—	1,710	—	1,554	—	1,377	—	1,197	—
Other^j	383	—	356	—	346	—	297	—	250	—
Subtotal	2,224	4.2	2,066	3.9	1,900	3.6	1,674	3.2	1,447	2.8
Region of residence^k
Northeast	230,044	410.3	232,022	413.7	234,097	417.4	235,593	420.7	235,337	421.4
Midwest	115,828	170.3	118,984	174.6	122,094	178.9	124,872	182.7	126,929	185.8
South	436,538	356.6	449,534	363.7	461,779	370.5	474,316	377.4	482,479	380.9
West	191,180	249.7	196,814	254.7	202,225	259.8	207,410	264.9	210,858	268.1
U.S. dependent areas	16,822	441.9	16,532	443.9	16,391	456.4	16,478	459.0	16,448	462.7
Total^l	990,412	303.0	1,013,886	308.3	1,036,586	313.7	1,058,669	319.0	1,072,051	321.9

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates and trends based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^b“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^cAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^dIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^eHispanic/Latino persons can be of any race.
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on address of residence at the end of the specified year (i.e., most recent known address).
^lIncludes persons whose race/ethnicity is unknown.

Table 16a. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States
	American Indian/Alaska Native		Asian^a		Black/African American		Hispanic/Latino^b		Native Hawaiian/other Pacific Islander		White		Multiracial		Total^c
	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d	No.	Rate^d
Gender
Male	2,390	—	13,156	—	281,564	—	196,810	—	750	—	264,233	—	39,268	—	798,697	—
Female	796	—	2,830	—	142,547	—	45,181	—	151	—	40,316	—	12,180	—	244,205	—
Transgender woman/girl^e	57	—	197	—	5,592	—	3,931	—	35	—	1,235	—	902	—	11,949	—
Transgender man/boy^e	4	—	9	—	219	—	108	—	0	—	124	—	45	—	509	—
Additional gender identity^f	1	—	6	—	93	—	67	—	0	—	48	—	28	—	243	—
Age at end of year
<13	7	1.7	100	3.5	843	11.8	192	1.4	3	2.6	182	0.7	117	4.6	1,444	2.8
13–14	1	1.4	33	7.8	374	32.4	85	3.9	0	0.0	88	2.1	59	16.8	640	7.6
15–19	11	6.3	96	8.7	2,311	81.0	763	14.9	7	16.7	421	3.9	169	21.8	3,778	18.0
20–24	98	54.0	387	31.3	13,509	444.5	5,835	118.9	26	60.6	3,323	28.9	1,003	144.9	24,186	112.0
25–29	268	135.4	1,185	77.4	33,053	961.4	16,688	336.3	80	160.9	10,895	87.6	3,279	538.9	65,455	281.8
30–34	374	206.0	1,792	106.4	46,183	1460.4	24,545	526.1	122	228.7	18,879	149.6	5,127	1094.9	97,029	424.9
35–39	392	244.3	1,877	115.2	40,805	1461.0	26,543	588.1	118	235.9	21,692	176.4	5,227	1356.2	96,659	442.8
40–44	377	258.8	2,019	137.9	40,593	1559.5	28,166	665.9	130	303.8	23,833	207.3	5,210	1606.7	100,348	494.1
45–49	345	246.0	2,392	168.1	43,155	1711.2	29,123	754.1	99	263.1	28,557	243.9	5,522	1994.0	109,234	547.0
50–54	452	317.0	2,191	176.7	54,228	2151.4	34,943	1031.4	103	288.6	45,675	356.2	7,415	3034.4	145,107	711.5
55–59	401	258.4	1,629	144.7	59,336	2284.4	33,620	1148.7	103	295.8	59,200	407.5	8,092	3444.3	162,542	752.4
60–64	264	182.6	1,115	109.2	46,380	1938.4	22,479	965.1	72	238.9	43,863	299.0	5,684	2696.4	120,013	577.0
≥65	258	81.2	1,382	52.8	49,245	949.8	23,115	473.5	73	113.5	49,348	117.1	5,519	1215.6	129,168	232.1
Transmission category^g
Male sex at birth (≥13 yrs at end of year)^h
Male-to-male sexual contact	1,740	—	11,252	—	187,976	—	150,900	—	672	—	217,022	—	29,508	—	599,433	—
Injection drug use	227	—	452	—	30,306	—	18,742	—	23	—	13,429	—	2,662	—	65,912	—
Male-to-male sexual contact and injection drug use	302	—	417	—	15,327	—	13,224	—	48	—	23,153	—	4,363	—	56,882	—
Heterosexual contactⁱ	159	—	1,068	—	49,490	—	16,185	—	35	—	9,947	—	3,122	—	80,035	—
Perinatal^j	5	—	60	—	2,930	—	1,223	—	3	—	568	—	338	—	5,135	—
Other^k	13	—	66	—	803	—	437	—	2	—	1,307	—	150	—	2,783	—
Subtotal	2,445	248.8	13,315	171.1	286,831	1772.7	200,711	832.6	783	311.5	265,426	316.0	40,143	1643.1	810,180	596.8
Female sex at birth (≥13 yrs at end of year)^h
Injection drug use	267	—	188	—	22,684	—	9,365	—	25	—	12,648	—	2,953	—	48,194	—
Heterosexual contactⁱ	510	—	2,459	—	115,289	—	34,215	—	123	—	26,577	—	8,735	—	188,033	—
Perinatal^j	9	—	63	—	3,565	—	1,350	—	0	—	633	—	388	—	6,015	—
Other^k	10	—	73	—	803	—	264	—	2	—	490	—	88	—	1,736	—
Subtotal	796	77.2	2,783	31.9	142,341	787.2	45,194	189.7	150	60.3	40,348	46.2	12,163	471.0	243,979	172.0
Child (<13 yrs at end of year)
Perinatal	6	—	61	—	697	—	180	—	3	—	141	—	106	—	1,194	—
Other^k	1	—	39	—	146	—	12	—	0	—	41	—	11	—	250	—
Subtotal	7	1.7	100	3.5	843	11.8	192	1.4	3	2.6	182	0.7	117	4.6	1,444	2.8
Region of residence^l
Northeast	144	111.9	3,466	88.8	89,494	1,413.6	73,061	869.9	64	282.6	53,710	149.0	15,055	1,487.6	235,337	421.4
Midwest	397	96.0	1,596	66.0	54,193	751.9	16,018	283.9	50	128.7	48,040	93.9	6,515	450.6	126,929	185.8
South	793	97.0	3,419	72.8	253,184	1,043.7	84,830	361.6	163	161.2	117,902	166.5	22,034	870.4	482,479	380.9
West	1,914	178.5	7,717	92.4	33,144	913.0	72,188	303.2	659	146.1	86,304	222.6	8,819	343.4	210,858	268.1
Total	3,248	133.5	16,198	83.6	430,015	1038.0	246,097	401.4	936	152.6	305,956	155.5	52,423	693.7	1,055,603	320.4

Note: Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^bHispanic/Latino persons can be of any race.
^cIncludes persons whose race/ethnicity is unknown.
^dRates are per 100,000 population. Rates are not calculated by gender or transmission category because of the lack of denominator data.
^e“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^fAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^gTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^hData include transgender and additional gender identity persons.
ⁱSexual contact with a person known to have, or with a risk factor for, HIV infection.
^jIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^kOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^lData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 16b. Persons living with diagnosed HIV infection, by race/ethnicity and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States and 6 dependent areas
	American Indian/Alaska Native	Asian^a	Black/African American	Hispanic/Latino^b	Native Hawaiian/other Pacific Islander	White	Multiracial	Total^c
	No.	No.	No.	No.	No.	No.	No.	No.
Gender
Male	2,392	13,213	281,755	208,010	774	264,307	39,288	810,267
Female	796	2,841	142,673	49,853	158	40,334	12,184	249,044
Transgender woman/girl^d	57	197	5,592	3,966	36	1,235	902	11,985
Transgender man/boy^d	4	9	219	111	0	124	45	512
Additional gender identity^e	1	6	93	67	0	48	28	243
Age at end of year
<13	7	100	844	193	4	182	117	1,447
13–14	1	33	374	88	0	88	59	643
15–19	11	96	2,314	781	7	421	170	3,800
20–24	98	387	13,511	6,048	27	3,324	1,003	24,403
25–29	268	1,186	33,059	17,289	83	10,896	3,280	66,068
30–34	374	1,801	46,198	25,421	130	18,884	5,128	97,943
35–39	392	1,882	40,823	27,537	121	21,699	5,229	97,688
40–44	377	2,025	40,614	29,555	134	23,837	5,213	101,775
45–49	345	2,401	43,196	30,755	101	28,563	5,525	110,929
50–54	453	2,202	54,288	37,358	108	45,695	7,420	147,624
55–59	401	1,641	59,374	36,418	104	59,218	8,094	165,411
60–64	265	1,123	46,421	24,704	74	43,878	5,687	122,308
≥65	258	1,389	49,316	25,860	75	49,363	5,522	132,012
Transmission category^f
Male sex at birth (≥13 yrs at end of year)^g
Male-to-male sexual contact	1,741	11,299	188,059	155,825	692	217,085	29,524	604,590
Injection drug use	227	458	30,341	21,884	24	13,432	2,663	69,099
Male-to-male sexual contact and injection drug use	302	419	15,333	13,955	50	23,157	4,365	57,629
Heterosexual contact^h	160	1,070	49,553	18,471	38	9,951	3,122	82,394
Perinatalⁱ	5	60	2,932	1,350	3	568	338	5,265
Other^j	13	66	803	462	2	1,307	150	2,808
Subtotal	2,447	13,372	287,021	211,946	808	265,500	40,163	821,785
Female sex at birth (≥13 yrs at end of year)^g
Injection drug use	267	190	22,698	10,262	25	12,652	2,953	49,114
Heterosexual contact^h	510	2,468	115,394	37,878	129	26,590	8,738	191,832
Perinatalⁱ	9	63	3,569	1,455	0	634	389	6,126
Other_j	10	73	806	273	2	490	88	1,747
Subtotal	796	2,794	142,467	49,868	156	40,366	12,167	248,819
Child (<13 yrs at end of year)
Perinatal	6	61	698	181	4	141	106	1,197
Other^j	1	39	146	12	0	41	11	250
Subtotal	7	100	844	193	4	182	117	1,447
Region of residence^k
Northeast	144	3,466	89,494	73,061	64	53,710	15,055	235,337
Midwest	397	1,596	54,193	16,018	50	48,040	6,515	126,929
South	793	3,419	253,184	84,830	163	117,902	22,034	482,479
West	1,914	7,717	33,144	72,188	659	86,304	8,819	210,858
U.S. dependent areas	2	68	317	15,910	32	92	24	16,448
Total	3,250	16,266	430,332	262,007	968	306,048	52,447	1,072,051

Note: Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^bHispanic/Latino persons can be of any race.
^cIncludes persons whose race/ethnicity is unknown.
^d“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender
^eAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”
^fTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^gData include transgender and additional gender identity persons.
^hSexual contact with a person known to have, or with a risk factor for, HIV infection.
ⁱIndividuals were aged ≥13 years at time of diagnosis of HIV infection.
^jOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
^kData are based on residence at death. When information on residence at death was not available, state at death (where a person’s death occurred) was used.

Table 17a. Persons aged ≥13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics, 2016–2020—United States
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at end of year
13–14	312	7.5	301	7.1	297	7.0	307	7.2	311	7.2
15–19	2,970	27.5	2,975	27.6	2,874	26.7	2,851	26.5	2,484	23.2
20–24	24,180	210.5	23,116	204.3	22,054	197.4	21,352	192.9	20,028	181.5
25–29	56,654	485.5	58,961	495.6	59,617	496.3	58,592	487.4	55,458	467.0
30–34	62,180	565.4	66,146	596.9	71,411	638.4	76,736	674.9	80,877	699.1
35–39	65,199	627.8	67,959	641.3	70,426	653.2	73,036	670.5	75,411	689.5
40–44	68,340	699.6	67,682	696.4	68,409	699.4	70,302	709.7	72,953	721.7
45–49	100,825	973.6	95,155	919.4	89,532	873.5	84,079	833.9	77,840	788.4
50–54	127,883	1,194.2	124,711	1,189.4	119,807	1,167.4	113,689	1,127.6	108,763	1,082.0
55–59	104,044	975.7	110,687	1037.3	117,372	1,101.2	123,071	1,156.8	125,217	1,191.2
60–64	67,133	722.0	73,524	771.6	79,467	817.8	85,326	866.1	91,643	918.5
≥65	60,766	279.0	69,127	306.9	78,288	336.4	88,685	368.6	99,195	399.6
Race/ethnicity
American Indian/Alaska Native	1,973	208.0	2,100	219.3	2,212	228.9	2,333	239.3	2,445	248.8
Asian^c	10,526	147.9	11,352	155.0	12,118	161.7	12,767	167.0	13,315	171.1
Black/African American	260,259	1,670.9	267,629	1,700.2	274,927	1,730.0	282,113	1,758.4	286,831	1,772.7
Hispanic/Latino^d	174,395	788.3	181,561	802.0	188,627	814.8	195,755	828.6	200,711	832.6
Native Hawaiian/other Pacific Islander	610	263.4	647	273.1	694	286.8	743	301.0	783	311.5
White	252,420	300.6	256,392	305.0	260,161	309.4	263,410	313.2	265,426	316.0
Multiracial	39,773	1,869.7	40,134	1,820.9	40,286	1,766.1	40,379	1,709.9	40,143	1,643.1
Transmission category^e
Male-to-male sexual contact	531,004	—	550,084	—	568,405	—	586,044	—	599,433	—
Injection drug use	68,935	—	68,166	—	67,525	—	66,954	—	65,912	—
Male-to-male sexual contact and injection drug use	56,977	—	57,124	—	57,180	—	57,361	—	56,882	—
Heterosexual contact^f	76,039	—	77,339	—	78,725	—	79,821	—	80,035	—
Perinatal^g	4,732	—	4,832	—	4,928	—	5,051	—	5,135	—
Other^h	2,799	—	2,800	—	2,791	—	2,794	—	2,783	—
Region of residenceⁱ
Northeast	161,984	702.6	163,829	709.3	165,728	716.6	167,279	723.4	167,483	725.2
Midwest	91,473	328.2	93,963	335.8	96,426	343.6	98,564	350.2	100,260	355.7
South	320,530	646.3	331,048	660.1	341,199	673.8	351,458	687.1	358,705	694.5
West	166,499	527.2	171,504	536.8	176,201	545.9	180,725	554.9	183,732	559.8
Subtotal	740,486	560.5	760,344	570.9	779,554	581.3	798,026	591.2	810,180	596.8
Female sex at birth^b
Age at end of year
13–14	367	9.1	368	9.1	369	9.1	343	8.4	329	8.0
15–19	1,669	16.1	1,561	15.1	1,484	14.4	1,387	13.4	1,294	12.6
20–24	5,603	51.5	5,265	49.0	4,895	46.0	4,630	43.8	4,158	39.4
25–29	11,596	102.9	11,378	99.3	11,192	97.0	10,689	92.8	9,997	88.0
30–34	16,819	155.2	16,538	152.0	16,197	148.0	16,294	146.9	16,152	143.3
35–39	24,147	232.2	23,658	223.3	23,061	214.2	22,375	206.0	21,248	195.1
40–44	28,730	289.9	28,124	285.3	28,046	283.3	27,678	276.4	27,395	268.6
45–49	34,890	330.7	34,521	327.3	33,494	320.0	32,776	318.0	31,394	310.9
50–54	38,058	343.3	37,723	347.9	37,361	352.7	36,664	353.0	36,344	351.4
55–59	31,325	277.8	33,266	295.0	35,000	310.9	36,601	325.9	37,325	336.5
60–64	20,136	198.3	22,278	214.2	24,452	231.0	26,464	247.1	28,370	262.1
≥65	17,554	64.0	20,273	71.8	23,196	79.8	26,595	88.7	29,973	97.2
Race/ethnicity
American Indian/Alaska Native	711	71.8	742	74.1	758	75.0	785	76.8	796	77.2
Asian^c	2,307	28.8	2,442	29.6	2,567	30.5	2,680	31.2	2,783	31.9
Black/African American	134,933	773.5	137,345	779.6	139,534	784.9	141,598	789.4	142,341	787.2
Hispanic/Latino^d	42,516	195.1	43,356	194.3	44,133	193.2	44,896	192.4	45,194	189.7
Native Hawaiian/other Pacific Islander	125	54.5	127	54.1	131	54.6	135	55.2	150	60.3
White	37,708	43.1	38,357	43.9	39,040	44.6	39,824	45.5	40,348	46.2
Multiracial	12,388	545.5	12,379	527.4	12,379	510.8	12,374	494.6	12,163	471.0
Transmission category^e
Injection drug use	49,201	—	48,995	—	48,837	—	48,727	—	48,195	—
Heterosexual contact^f	174,674	—	178,746	—	182,501	—	186,172	—	188,033	—
Perinatal^g	5,351	—	5,532	—	5,713	—	5,876	—	6,015	—
Other^h	1,668	—	1,680	—	1,697	—	1,722	—	1,736	—
Region of residenceⁱ
Northeast	67,698	274.5	67,871	274.9	68,097	275.7	68,067	275.7	67,648	274.5
Midwest	23,871	82.3	24,552	84.4	25,206	86.4	25,908	88.6	26,319	89.9
South	115,016	219.5	117,550	221.8	119,722	223.6	122,102	225.7	123,110	225.3
West	24,309	75.8	24,980	77.0	25,722	78.5	26,419	80.0	26,902	80.8
Subtotal	230,894	167.1	234,953	168.8	238,747	170.3	242,496	171.9	243,979	172.0
Total	971,380	359.4	995,297	365.4	1,018,301	371.3	1,040,522	376.9	1,054,159	379.7

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data.
^bData include transgender and additional gender identity persons.
^cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fSexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 17b. Persons aged ≥13 years living with diagnosed HIV infection, by year, sex assigned at birth, and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016		2017		2018		2019		2020 (COVID-19 Pandemic)
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Male sex at birth^b
Age at end of year
13–14	314	7.4	303	7.1	301	7.0	310	7.2	313	7.2
15–19	2,996	27.4	2,997	27.5	2,901	26.7	2,868	26.4	2,498	23.1
20–24	24,444	210.3	23,344	203.9	22,252	197.0	21,549	192.6	20,206	181.1
25–29	57,254	485.5	59,521	495.1	60,181	496.0	59,149	487.0	55,953	466.4
30–34	62,890	566.3	66,826	597.5	72,081	638.8	77,441	675.0	81,605	699.0
35–39	66,170	630.3	68,860	643.2	71,259	654.7	73,826	671.6	76,190	690.5
40–44	69,468	703.0	68,767	699.6	69,461	702.5	71,326	712.4	73,950	724.1
45–49	102,504	978.6	96,658	923.6	90,855	876.9	85,316	837.0	78,982	791.4
50–54	130,000	1,200.5	126,774	1,195.6	121,818	1,173.9	115,548	1,133.4	110,548	1,087.8
55–59	105,775	981.3	112,500	1043.2	119,269	1,107.3	125,086	1,163.4	127,218	1,197.4
60–64	68,354	727.0	74,827	776.7	80,850	823.1	86,771	871.4	93,188	924.1
≥65	62,041	281.0	70,543	309.1	79,822	338.5	90,425	370.9	101,134	402.2
Race/ethnicity
American Indian/Alaska Native	1,975	—	2,102	—	2,214	—	2,335	—	2,447	—
Asian^c	10,567	—	11,397	—	12,168	—	12,824	—	13,372	—
Black/African American	260,435	—	267,801	—	275,110	—	282,299	—	287,021	—
Hispanic/Latino^d	185,794	—	192,804	—	199,778	—	206,980	—	211,946	—
Native Hawaiian/other Pacific Islander	631	—	671	—	719	—	768	—	808	—
White	252,484	—	256,459	—	260,227	—	263,484	—	265,500	—
Multiracial	39,792	—	40,155	—	40,303	—	40,397	—	40,163	—
Transmission category^e
Male-to-male sexual contact	535,741	—	554,845	—	573,263	—	591,073	—	604,590	—
Injection drug use	72,548	—	71,657	—	70,888	—	70,228	—	69,099	—
Male-to-male sexual contact and injection drug use	57,809	—	57,919	—	57,945	—	58,120	—	57,629	—
Heterosexual contact^f	78,423	—	79,709	—	81,079	—	82,192	—	82,394	—
Perinatal^g	4,864	—	4,962	—	5,058	—	5,183	—	5,265	—
Other^h	2,826	—	2,827	—	2,817	—	2,820	—	2,808	—
Region of residenceⁱ
Northeast	161,984	702.6	163,829	709.3	165,728	716.6	167,279	723.4	167,483	725.2
Midwest	91,473	328.2	93,963	335.8	96,426	343.6	98,564	350.2	100,260	355.7
South	320,530	646.3	331,048	660.1	341,199	673.8	351,458	687.1	358,705	694.5
West	166,499	527.2	171,504	536.8	176,201	545.9	180,725	554.9	183,732	559.8
U.S. dependent areas	11,724	763.1	11,576	765.3	11,496	781.3	11,589	784.3	11,605	789.2
Subtotal	752,210	562.9	771,920	573.1	791,050	583.5	809,615	593.3	821,785	598.9
Female sex at birth^b
Age at end of year
13–14	368	9.0	372	9.1	373	9.1	344	8.3	330	7.9
15–19	1,690	16.1	1,584	15.2	1,499	14.4	1,396	13.4	1,302	12.5
20–24	5,687	51.6	5,333	49.0	4,964	46.1	4,683	43.8	4,197	39.3
25–29	11,759	103.2	11,524	99.4	11,323	97.1	10,817	92.9	10,115	88.1
30–34	17,074	155.9	16,769	152.6	16,404	148.4	16,495	147.3	16,338	143.6
35–39	24,579	233.6	24,043	224.4	23,405	215.1	22,665	206.6	21,498	195.5
40–44	29,273	291.7	28,626	286.9	28,513	284.6	28,112	277.5	27,825	269.8
45–49	35,627	333.6	35,206	329.8	34,151	322.6	33,406	320.3	31,947	312.7
50–54	38,965	347.1	38,586	351.5	38,163	355.9	37,413	355.8	37,076	354.2
55–59	32,164	281.9	34,106	299.0	35,845	314.8	37,486	329.9	38,193	340.3
60–64	20,649	200.9	22,827	216.9	25,091	234.3	27,156	250.7	29,120	266.0
≥65	18,143	65.2	20,924	73.1	23,905	81.1	27,407	90.2	30,878	98.8
Race/ethnicity
American Indian/Alaska Native	711	—	742	—	758	—	785	—	796	—
Asian^c	2,318	—	2,453	—	2,578	—	2,691	—	2,794	—
Black/African American	135,060	—	137,470	—	139,659	—	141,725	—	142,467	—
Hispanic/Latino^d	47,433	—	48,136	—	48,857	—	49,613	—	49,868	—
Native Hawaiian/other Pacific Islander	132	—	134	—	136	—	141	—	156	—
White	37,725	—	38,376	—	39,058	—	39,843	—	40,366	—
Multiracial	12,392	—	12,383	—	12,384	—	12,377	—	12,167	—
Transmission category^e
Injection drug use	50,248	—	49,985	—	49,792	—	49,670	—	49,114	—
Heterosexual contact^f	178,573	—	182,568	—	186,307	—	189,994	—	191,832	—
Perinatal^g	5,477	—	5,655	—	5,829	—	5,984	—	6,126	—
Other^h	1,680	—	1,692	—	1,708	—	1,732	—	1,747	—
Region of residenceⁱ
Northeast	67,698	274.5	67,871	274.9	68,097	275.7	68,067	275.7	67,648	274.5
Midwest	23,871	82.3	24,552	84.4	25,206	86.4	25,908	88.6	26,319	89.9
South	115,016	219.5	117,550	221.8	119,722	223.6	122,102	225.7	123,110	225.3
West	24,309	75.8	24,980	77.0	25,722	78.5	26,419	80.0	26,902	80.8
U.S. dependent areas	5,084	297.3	4,947	293.9	4,889	298.8	4,884	296.9	4,840	295.1
Subtotal	235,978	168.7	239,900	170.3	243,636	171.8	247,380	173.3	248,819	173.4
Total	988,188	361.3	1,011,820	367.1	1,034,686	373.0	1,056,995	378.6	1,070,604	381.4

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and rates based on these numbers, should be interpreted with caution.

^aRates are per 100,000 population. Rates are not calculated by transmission category because of the lack of denominator data. Rates by race/ethnicity are not provided because U.S. census information is limited for U.S. dependent areas.
^bData include transgender and additional gender identity persons.
^cIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^dHispanic/Latino persons can be of any race.
^eTransmission category is classified based on a hierarchy of the risk factors most likely responsible for HIV transmission; classification is determined based on the person’s sex assigned at birth. Data have been statistically adjusted to account for missing transmission category, therefore values may not sum to column subtotals and total.
^fSexual contact with a person known to have, or with a risk factor for, HIV infection.
^gIncludes individuals aged ≥13 years at time of diagnosis of HIV infection.
^hOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified.
ⁱData are based on address of residence at the end of the specified year (i.e., most recent known address).

Table 18a. Transgender and additional gender identity persons aged ≥13 years living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at end of year
13–14	0	0	0	0	1
15–19	103	93	68	66	49
20–24	853	798	770	738	710
25–29	1,861	1,904	1,904	1,814	1,718
30–34	1,602	1,816	2,012	2,266	2,494
35–39	1,373	1,466	1,583	1,705	1,784
40–44	1,098	1,125	1,197	1,272	1,410
45–49	1,096	1,091	1,106	1,153	1,145
50–54	905	991	1,034	1,031	1,076
55–59	557	611	693	785	816
60–64	268	307	343	376	446
≥65	137	174	206	258	299
Race/ethnicity
American Indian/Alaska Native	40	42	49	53	57
Asian^b	143	162	170	182	197
Black/African American	4,592	4,857	5,118	5,368	5,592
Hispanic/Latino^c	3,183	3,342	3,542	3,756	3,931
Native Hawaiian/other Pacific Islander	24	26	29	33	35
White	1,018	1,078	1,122	1,182	1,235
Multiracial	853	869	886	890	901
Exposure category^d
Sexual contact^e	8,095	8,590	9,103	9,624	10,102
Injection drug use	16	19	23	24	24
Sexual contact^e and injection drug use	1,572	1,583	1,597	1,613	1,595
Perinatal^f	22	22	22	21	20
Other^g	148	162	171	182	207
Region of residence^h
Northeast	2,627	2,751	2,898	2,999	3,091
Midwest	1,324	1,403	1,496	1,546	1,624
South	3,521	3,729	3,885	4,095	4,314
West	2,381	2,493	2,637	2,824	2,919
Subtotal	9,853	10,376	10,916	11,464	11,948
Transgender man^a
Age at end of year
13–14	1	1	0	0	1
15–19	6	7	7	5	3
20–24	16	19	22	29	39
25–29	44	59	71	74	69
30–34	54	44	61	82	92
35–39	53	64	65	67	75
40–44	42	42	51	54	57
45–49	44	47	50	52	48
50–54	46	47	46	44	47
55–59	28	28	25	34	38
60–64	16	20	26	22	24
≥65	11	11	12	15	16
Race/ethnicity
American Indian/Alaska Native	4	4	4	4	4
Asian^b	4	6	8	9	9
Black/African American	166	174	194	211	219
Hispanic/Latino^c	76	81	89	101	108
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	75	86	102	111	124
Multiracial	36	38	39	42	45
Exposure category^d
Sexual contact^e	257	282	325	359	382
Injection drug use	5	6	8	9	10
Sexual contact^e and injection drug use	64	63	60	61	62
Perinatal^f	18	18	18	17	19
Other^g	17	20	25	32	36
Region of residence^h
Northeast	71	74	78	87	91
Midwest	104	109	119	124	125
South	105	117	134	150	173
West	81	89	105	117	120
Subtotal	361	389	436	478	509
Additional gender identityⁱ
Age at end of year
13–14	0	0	0	0	0
15–19	4	2	5	5	2
20–24	13	15	19	24	27
25–29	34	34	34	33	36
30–34	24	27	31	45	53
35–39	15	28	34	38	34
40–44	24	16	15	12	16
45–49	14	23	21	20	25
50–54	12	13	13	18	17
55–59	15	14	15	14	10
60–64	6	7	8	7	12
≥65	5	5	7	10	11
Race/ethnicity
American Indian/Alaska Native	0	0	1	1	1
Asian^b	1	2	5	5	6
Black/African American	66	73	78	85	93
Hispanic/Latino^c	47	53	55	63	67
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	31	34	39	44	48
Multiracial	21	22	24	28	28
Exposure category^d
Sexual contact^e	138	156	175	197	211
Injection drug use	1	1	1	1	1
Sexual contact^e and injection drug use	24	23	22	23	24
Perinatal^f	2	2	2	2	2
Other^g	1	2	2	3	5
Region of residence^h
Northeast	88	107	128	136	139
Midwest	20	22	21	31	38
South	44	40	39	42	43
West	14	15	14	17	23
Subtotal	166	184	202	226	243
Total	10,380	10,949	11,554	12,168	12,700

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^cHispanic/Latino persons can be of any race.
^dRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^fIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
^gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^hData are based on address of residence at the end of the specified year (i.e., most recent known address).
ⁱAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 18b. Transgender and additional gender identity persons aged ≥13 years living with diagnosed HIV infection, by year and selected characteristics, 2016–2020—United States and 6 dependent areas
	2016	2017	2018	2019	2020 (COVID-19 Pandemic)
	No.	No.	No.	No.	No.
Transgender woman^a
Age at end of year
13–14	0	0	0	0	1
15–19	103	93	68	66	49
20–24	856	801	774	743	715
25–29	1,866	1,907	1,906	1,816	1,719
30–34	1,607	1,824	2,019	2,272	2,500
35–39	1,379	1,471	1,586	1,707	1,789
40–44	1,100	1,127	1,202	1,278	1,417
45–49	1,098	1,093	1,106	1,154	1,147
50–54	910	994	1,035	1,034	1,077
55–59	561	617	699	790	821
60–64	269	308	344	378	449
≥65	139	176	208	259	300
Race/ethnicity
American Indian/Alaska Native	40	42	49	53	57
Asian^b	143	162	170	182	197
Black/African American	4,592	4,857	5,118	5,368	5,592
Hispanic/Latino^c	3,218	3,377	3,573	3,788	3,966
Native Hawaiian/other Pacific Islander	24	26	29	34	36
White	1,018	1,078	1,122	1,182	1,235
Multiracial	853	869	886	890	901
Exposure category^d
Sexual contact^e	8,123	8,618	9,128	9,652	10,133
Injection drug use	16	19	23	24	24
Sexual contact^e and injection drug use	1,579	1,590	1,603	1,618	1,600
Perinatal^f	22	22	22	21	20
Other^g	148	162	171	182	207
Region of residence^h
Northeast	2,627	2,751	2,898	2,999	3,091
Midwest	1,324	1,403	1,496	1,546	1,624
South	3,521	3,729	3,885	4,095	4,314
West	2,381	2,493	2,637	2,824	2,919
US dependent areas	35	35	31	33	36
Subtotal	9,888	10,411	10,947	11,497	11,984
Transgender man^a
Age at end of year
13–14	1	1	0	0	1
15–19	7	8	8	5	3
20–24	16	19	22	30	40
25–29	44	59	71	74	69
30–34	54	44	61	82	92
35–39	53	64	65	67	75
40–44	42	42	52	55	58
45–49	44	47	50	52	48
50–54	46	47	46	44	47
55–59	28	28	25	34	38
60–64	16	20	26	22	24
≥65	11	11	12	15	17
Race/ethnicity
American Indian/Alaska Native	4	4	4	4	4
Asian^b	4	6	8	9	9
Black/African American	166	174	194	211	219
Hispanic/Latino^c	77	82	91	103	111
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	75	86	102	111	124
Multiracial	36	38	39	42	45
Exposure category^d
Sexual contact^e	257	282	326	360	383
Injection drug use	5	6	8	9	10
Sexual contact^e and injection drug use	64	63	60	61	63
Perinatal^f	19	19	19	18	20
Other^g	17	20	25	32	36
Region of residence^h
Northeast	71	74	78	87	91
Midwest	104	109	119	124	125
South	105	117	134	150	173
West	81	89	105	117	120
US dependent areas	1	1	2	2	3
Subtotal	362	390	438	480	512
Additional gender identity^e
Age at end of year
13–14	0	0	0	0	0
15–19	4	2	5	5	2
20–24	13	15	19	24	27
25–29	34	34	34	33	36
30–34	25	27	32	45	53
35–39	15	28	34	38	34
40–44	24	16	15	12	16
45–49	14	23	21	20	25
50–54	12	13	13	18	17
55–59	15	14	15	14	10
60–64	6	7	8	7	12
≥65	5	5	7	10	11
Race/ethnicity
American Indian/Alaska Native	0	0	1	1	1
Asian^b	1	2	5	5	6
Black/African American	66	73	78	85	93
Hispanic/Latino^c	48	53	56	63	67
Native Hawaiian/other Pacific Islander	0	0	0	0	0
White	31	34	39	44	48
Multiracial	21	22	24	28	28
Exposure category^d
Sexual contact^e	139	156	176	197	211
Injection drug use	1	1	1	1	1
Sexual contact^e and injection drug use	24	23	22	23	24
Perinatal^f	2	2	2	2	2
Other^g	1	2	2	3	5
Region of residence^h
Northeast	88	107	128	136	139
Midwest	20	22	21	31	38
South	44	40	39	42	43
West	14	15	14	17	23
US dependent areas	1	0	1	0	0
Subtotal	167	184	203	226	243
Total	10,417	10,985	11,588	12,203	12,739

Note. Data for the year 2020 are preliminary and based on deaths reported to CDC as of December 2021. Data for 2020 should be interpreted with caution due to the impact of the COVID-19 pandemic on access to HIV testing, care-related services, and case surveillance activities in state/local jurisdictions. Numbers less than 12, and trends based on these numbers, should be interpreted with caution.

^a“Transgender woman” includes individuals who were assigned “male” sex at birth but have ever identified as “female” gender. “Transgender man” includes individuals who were assigned “female” sex at birth but have ever identified as “male” gender.
^bIncludes Asian/Pacific Islander legacy cases (see Technical Notes).
^cHispanic/Latino persons can be of any race.
^dRisk factor data for transgender and additional gender identity adults and adolescents are presented using the exposure category classification which is meant to convey all the known ways the person could have been exposed to HIV. Exposure categories are mutually exclusive and have no presumed hierarchical order of probability, except for rare circumstances where route of transmission has been confirmed through investigation. See Technical Notes for more information on exposure categories.
^eFor persons assigned “male” sex at birth, sexual contact with any person. For persons assigned “female” sex at birth, sexual contact with a person assigned “male” sex at birth.
^fIndividuals were ≥13 years of age at time of diagnosis of HIV infection.
^gOther risk factors including hemophilia, blood transfusion, and risk factor not reported or not identified. Data were not statistically adjusted to account for missing exposure category; therefore, case counts for “Other” might be high.
^hData are based on address of residence at the end of the specified year (i.e., most recent known address).
ⁱAdditional gender identity examples include “bigender,” “gender queer,” and “two-spirit.”

Table 19a. Persons aged 13–24 years living with diagnosed HIV infection, by age at end of year and sex assigned at birth, and selected characteristics, year-end 2020 (COVID-19 Pandemic)—United States
	13–14 years		15–17 years		18–19 years		20–22 years		23–24 years		Total
	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a	No.	Rate^a
Sex at birth
Male	311	7.2	706	11.0	1,778	41.3	8,867	134.3	11,161	252.0	22,823	87.7
Female	329	8.0	637	10.4	657	15.9	1,951	30.9	2,207	52.0	5,781	23.2
Race/Ethnicity
American Indian/Alaska Native	1	1.4	1	1.0	10	14.2	47	42.9	51	71.0	110	25.7
Asian^b	33	7.8	53	8.1	43	9.5	171	24.1	216	40.9	516	18.6
Black/African American	374	32.4	836	49.5	1,475	126.3	6,268	344.0	7,241	594.9	16,194	229.8
Hispanic/Latino^c	85	3.9	226	7.3	537	26.6	2,523	84.9	3,312	171.2	6,683	54.9
Native Hawaiian/Other Pacific Islander	0	0.0	2	7.9	5	30.4	11	43.2	15	86.0	33	32.4
White	88	2.1	164	2.5	257	5.8	1,351	19.7	1,972	42.5	3,832	14.4
Multiracial	59	16.8	61	12.7	108	36.5	445	104.1	558	210.6	1,231	67.7
Transmission Category^d
Male sex at birth^e
Male-to-male sexual contact	5	—	238	—	1,341	—	7,743	—	9,813	—	19,140	—
Injection drug use	0	—	2	—	11	—	77	—	127	—	218	—
Male-to-male sexual contact and injection drug use	0	—	4	—	27	—	202	—	362	—	594	—
Heterosexual contact^f	0	—	10	—	35	—	222	—	327	—	595	—
Perinat

Diagnoses of HIV Infection in the United States and Dependent Areas, 2020: Tables

Download the Full Report pdf icon[PDF – 6 MB]

Report Contents

Other Reports